<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7993375</article-id><article-id pub-id-type="pmid">33730937</article-id><article-id pub-id-type="doi">10.1080/14756366.2021.1899168</article-id><article-id pub-id-type="publisher-id">1899168</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Discovery of novel quinoline-based analogues of combretastatin A-4 as tubulin polymerisation inhibitors with apoptosis inducing activity and potent anticancer effect</article-title><alt-title alt-title-type="left-running-head">T. S. Ibrahim et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3049-4617</contrib-id><name><surname>Ibrahim</surname><given-names>Tarek S.</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="aff" rid="AF0002">b</xref><xref ref-type="corresp" rid="AN0001"/></contrib><contrib contrib-type="author"><name><surname>Hawwas</surname><given-names>Mohamed M.</given-names></name><xref ref-type="aff" rid="AF0003">c</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4178-0341</contrib-id><name><surname>Malebari</surname><given-names>Azizah M.</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1091-2885</contrib-id><name><surname>Taher</surname><given-names>Ehab S.</given-names></name><xref ref-type="aff" rid="AF0003">c</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9825-3465</contrib-id><name><surname>Omar</surname><given-names>Abdelsattar M.</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="aff" rid="AF0004">d</xref></contrib><contrib contrib-type="author"><name><surname>Neamatallah</surname><given-names>Thikryat</given-names></name><xref ref-type="aff" rid="AF0005">e</xref></contrib><contrib contrib-type="author"><name><surname>Abdel-Samii</surname><given-names>Zakaria K.</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>Safo</surname><given-names>Martin K.</given-names></name><xref ref-type="aff" rid="AF0006">f</xref><xref ref-type="corresp" rid="AN0002"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4332-6345</contrib-id><name><surname>Elshaier</surname><given-names>Yaseen A. M. M.</given-names></name><xref ref-type="aff" rid="AF0007">g</xref></contrib><aff id="AF0001"><label>a</label><institution>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University</institution>, <city>Jeddah</city>, <country>Saudi Arabia</country></aff><aff id="AF0002"><label>b</label><institution>Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University</institution>, <city>Zagazig</city>, <country>Egypt</country></aff><aff id="AF0003"><label>c</label><institution>Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University</institution>, <city>Assiut</city>, <country>Egypt</country></aff><aff id="AF0004"><label>d</label><institution>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University</institution>, <city>Cairo</city>, <country>Egypt</country></aff><aff id="AF0005"><label>e</label><institution>Department of Pharmacology and toxicology, Faculty of Pharmacy, King Abdulaziz University</institution>, <city>Jeddah</city>, <country>Saudi Arabia</country></aff><aff id="AF0006"><label>f</label><institution>Institute for Structural Biology, Drug Discovery and Development, Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University</institution>, <city>Richmond</city>, <state>VA</state>, <country>USA</country></aff><aff id="AF0007"><label>g</label><institution>Department of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Sadat City</institution>, <city>Menoufia</city>, <country>Egypt</country></aff></contrib-group><author-notes><corresp id="AN0001">CONTACT Tarek S. Ibrahim <email>tmabrahem@kau.edu.sa, tarekeldeeb1976@yahoo.com</email><institution>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University</institution>, <city>Jeddah</city>, <postal-code>21589</postal-code>, <country>Saudi Arabia</country></corresp><corresp id="AN0002">Martin K. Safo <email>msafo@vcu.edu</email><institution>Institute for Structural Biology, Drug Discovery and Development, Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University</institution>, <city>Richmond</city>, <state>VA</state><postal-code>23219</postal-code>, <country>USA</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>18</day><month>3</month><year>2021</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2021</year></pub-date><volume>36</volume><issue>1</issue><fpage seq="75">802</fpage><lpage>818</lpage><permissions><copyright-statement>&#x000a9; 2021 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_36_1899168.pdf"/><abstract><title>Abstract</title><p>A new series of quinoline derivatives of combretastatin A-4 have been designed, synthesised and demonstrated as tubulin polymerisation inhibitors. These novel compounds showed significant antiproliferative activities, among them, <bold>12c</bold> exhibited the most potent inhibitory activity against different cancer cell lines (MCF-7, HL-60, HCT-116 and HeLa) with IC<sub>50</sub> ranging from 0.010 to 0.042&#x02009;&#x000b5;M, and with selectivity profile against MCF-10A non-cancer cells. Further mechanistic studies suggest that <bold>12c</bold> can inhibit tubulin polymerisation and cell migration, leading to G<sub>2</sub>/M phase arrest. Besides, <bold>12c</bold> induces apoptosis <italic>via</italic> a mitochondrial-dependant apoptosis pathway and caused reactive oxygen stress generation in MCF-7 cells. These results provide guidance for further rational development of potent tubulin polymerisation inhibitors for the treatment of cancer.<list list-type="bullet"><title>Highlights</title><list-item><p>A novel series of quinoline derivatives of combretastatin A-4 have been designed and synthesised.</p></list-item><list-item><p>Compound <bold>12c</bold> showed significant antiproliferative activities against different cancer cell lines.</p></list-item><list-item><p>Compound <bold>12c</bold> effectively inhibited tubulin polymerisation and competed with [<sup>3</sup>H] colchicine in binding to tubulin.</p></list-item><list-item><p>Compound <bold>12c</bold> arrested the cell cycle at G<sub>2</sub>/M phase, effectively inducing apoptosis and inhibition of cell migration.</p></list-item></list></p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><fig id="UF0001" orientation="portrait" position="anchor"><graphic content-type="color" xlink:href="IENZ_A_1899168_UF0001_C"/></fig></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Combretastatin A-4</kwd><kwd>quinoline</kwd><kwd>apoptosis</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution-wrap><institution>Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah</institution><institution-id institution-id-type="open-funder-registry">10.13039/501100004686</institution-id></institution-wrap></funding-source><award-id>RG-18&#x02013;166-41</award-id></award-group><funding-statement>This project was funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, under grant number [RG-18&#x02013;166-41]. The authors, therefore, gratefully acknowledge DSR technical and financial support.</funding-statement></funding-group></support-group><counts><fig-count count="10"/><table-count count="2"/><page-count count="17"/><word-count count="10571"/></counts></article-meta></front><body><sec id="S0001" disp-level="1"><label>1.</label><title>Introduction</title><p>Cancer is a disease of an uncontrolled growth and abnormal division of cells, which leads to death. In recent years, targeted antineoplastic agents have become an effective treatment choice for cancer<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref>, with pharmaceutical companies focussing on targeted therapies against different and special cancer types<xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref>. Tubulin polymerisation inhibitors represent one of the most well-known and potential examples of such targeted cancer therapies<xref rid="CIT0003" ref-type="bibr"><sup>3</sup></xref>. Tubulin is a globular protein that performs a substantial function in cell mitosis. Microtubules (MTs), which represent the basic constituents of eukaryotic cell, are cytoskeletons constructed by the association of &#x003b1;- and &#x003b2;-tubulin heterodimers with a head and tail pattern to form hollow cylindrical tubes (nearly 25&#x02009;nm in diameter)<xref rid="CIT0004" ref-type="bibr"><sup>4&#x02013;7</sup></xref>. MTs play a crucial role in many fundamental cellular activities, such as motility, cell formation, cell secretion, signalling, maintenance of cell shape, regulation of intracellular transport and cell division<xref rid="CIT0008" ref-type="bibr"><sup>8&#x02013;10</sup></xref>. Due to these multiple functions, microtubule system has become an attractive target for cancer chemotherapy<xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="CIT0012" ref-type="bibr"><sup>12</sup></xref>. Disruption of MTs or tubulin dynamics exposes the cell to mitotic arrest of the cell cycle at G<sub>2</sub>/M phase, and consequently induction of cellular apoptosis<xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref>. Several microtubule-interfering agents (MIAs) have been identified, e.g. paclitaxel, vincristine, and colchicine that are obtained from the natural products, taxol, vinca and colchicine, respectively. MIAs are known to bind to tubulin at specific binding sites that are classified as taxol, vinca and colchicine sites to either enhance or inhibit tubulin polymerisation.<xref rid="CIT0015" ref-type="bibr"><sup>15</sup></xref> For example, microtubule stabilisers, e.g. paclitaxel stimulate microtubule polymerisation<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref>, while microtubule destabilizers, e.g. colchicine, and the vinca alkaloids vinblastine and vincristine inhibit polymerisation of microtubules<xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref>.</p><p>Significant attention is now focussed on colchicine binding site inhibitors due to their positive impact on ABC-transporter-mediated drug resistance<xref rid="CIT0018" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="CIT0019" ref-type="bibr"><sup>19</sup></xref>. Combretastatin A-4 (CA-4), (<bold>1</bold>, <xref ref-type="fig" rid="F0001">Figure 1</xref>) has been reported as the most potent antimitotic agent of this family against several tumour cells<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>. CA-4 was first isolated from the bark of the willow tree <italic>Combretum caffrum</italic> from South Africa in 1989<xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref>. CA-4 has a vascular disrupting activity against tumour cell vasculature by preventing blood supply to solid tumour, resulting in apoptosis<xref rid="CIT0022" ref-type="bibr"><sup>22&#x02013;24</sup></xref>. Given its structural simplicity, CA-4 has been studied as a lead pharmacophore for deciphering tubulin functions and properties<xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref>. Phases II and III clinical studies are currently ongoing with tubulin-targeted drugs<xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="CIT0026" ref-type="bibr"><sup>26</sup></xref>. Structure activity relationships (SAR) studies with CA-4 have revealed three important structural features (<xref ref-type="fig" rid="F0001">Figure 1</xref>). These include: (i) a 3,4,5-trimethoxy moiety on ring A that is essential for activity; (ii) a <italic>cis</italic>-configuration of both aromatic rings that is essential for activity (<italic>trans</italic>-orientation is inactive); (iii) the presence of small substituent on ring B, e.g. methoxy group that is important for activity. The <italic>cis</italic>-alkene configuration in CA-4 allows the aromatic rings to assume optimal binding orientation for interactions with the colchicine binding site. Unfortunately, the <italic>cis</italic> configuration of CA-4 has a propensity for undergoing transformation to the inactive <italic>trans</italic> configuration upon storage and during <italic>in&#x000a0;vivo</italic> metabolism. To overcome this, many structural modifications of CA-4 have been undertaken where the <italic>cis</italic> double bond is replaced with heterocycles, either monocyclic, such as oxadiazole, isoxazole and imidazole, resulting in compounds, such as <bold>1</bold>, <bold>2</bold> and <bold>3</bold> respectively (<xref ref-type="fig" rid="F0001">Figure 1</xref>)<xref rid="CIT0027" ref-type="bibr"><sup>27&#x02013;33</sup></xref> or fused heterocyclic, such as pyrazolopyridines<xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref>, triazolopyridines<xref rid="CIT0035" ref-type="bibr"><sup>35</sup></xref> and triazolothiadiazine derivatives<xref rid="CIT0036" ref-type="bibr"><sup>36</sup></xref>. These compounds, like CA-4 showed pronounced activity against a panel of cancer cell lines.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>(A) Chemical structure of CA-4 and its analogues; (B) tubulin targeting agents bearing quinoline moiety.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1899168_F0001_C"/></fig><p>Quinoline derivatives are popular for the treatment of malaria<xref rid="CIT0037" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="CIT0038" ref-type="bibr"><sup>38</sup></xref>. Moreover, quinoline heterocyclic containing compounds demonstrate potent anticancer activities with different modes of actions, including inhibition of proteasome, tyrosine kinases, and tubulin polymerisation<xref rid="CIT0039" ref-type="bibr"><sup>39&#x02013;41</sup></xref>. Previous studies have reported the antiproliferative activity of CA-4, isoCA-4 or chalcone compounds containing quinoline scaffold, either as ring A bioisoster, e.g. <bold>4a</bold><xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref> and <bold>4b</bold><xref rid="CIT0042" ref-type="bibr"><sup>42</sup></xref> or ring B bioisoster, e.g. <bold>4c</bold><xref rid="CIT0043" ref-type="bibr"><sup>43&#x02013;45</sup></xref> and <bold>4d</bold><xref rid="CIT0046" ref-type="bibr"><sup>46</sup></xref>. These compounds demonstrate the potential of the quinoline ring as a template for developing more promising tubulin polymerisation inhibitors and antiproliferative agents.</p><p>In this work, we optimised CA-4 into a series of novel hybrid quinoline derivatives as potent tubulin inhibitor, which involves introducing a rigid oxazolone or imidazolone between rings A and B to maintain the cis configuration, as well as targeting the quinolyl moiety (ring B), by varying the electronic substituents effect while maintaining the 3,4,5-trimethoxyphenyl moiety as present in ring A of CA-4 (<xref ref-type="fig" rid="F0002">Figure 2</xref>). Following, we synthesised several analogues that constitute two classes of compounds: the oxazolones (Compounds <bold>12a&#x02013;h)</bold> and the imidazolones <bold>(</bold>Compounds <bold>13a&#x02013;h</bold>). The compounds have been screened for their antiproliferative activities against a variety of cancer cell lines, as well as studied for their mechanism of action. We expect the results to lead to better understanding of the mechanistic mode of the compounds&#x02019; activity against tubulin and provide guidance for further development of potent anticancer drugs.</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Structure of CA-4 and our rationalised compounds.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1899168_F0002_C"/></fig></sec><sec id="S0002" disp-level="1"><label>2.</label><title>Experimental section</title><sec id="S0002-S2001" disp-level="2"><label>2.1.</label><title>Chemistry</title><p>Melting points were determined with a Gallenkamp (London, UK) melting point apparatus and are uncorrected. IR spectra (KBr, cm<sup>&#x02212;1</sup>) were recorded on Bruker Vector, 22FT-IR [Fourier Transform Infra-red (FTIR), Germany] spectrometer. Unless otherwise specified, proton (<sup>1</sup>H) and carbon (<sup>13</sup>C) NMR spectra were recorded at room temperature in base filtered CDCl<sub>3</sub> on a spectrometer operating at 400 &#x00026; 300&#x02009;MHz for proton and 100 &#x00026; 75&#x02009;MHz for carbon nuclei. The signal due to residual CHCl<sub>3</sub> appearing at &#x003b4; H 7.26 and (CH<sub>3</sub>)<sub>2</sub>SO appearing at &#x003b4; H 2.5 and the central resonance of the CDCl<sub>3</sub> &#x0201c;triplet&#x0201d; appearing at &#x003b4; C 77.0 and for (CD<sub>3</sub>)<sub>2</sub>SO &#x0201c;multiplet&#x0201d; appearing at &#x003b4; C 39.0 were used to reference 1H and <sup>13</sup>C NMR spectra, respectively. <sup>1</sup>H NMR data are recorded as follows: chemical shift (&#x003b4;) [multiplicity, coupling constant(s) J (Hz), relative integral] where multiplicity is defined as s&#x02009;=&#x02009;singlet; d&#x02009;=&#x02009;doublet; t&#x02009;=&#x02009;triplet; q&#x02009;=&#x02009;quartette; and m&#x02009;=&#x02009;multiplet or combinations of the above. Elemental analyses were determined using Manual Elemental Analyser Heraeus (Germany) and Automatic Elemental Analyser CHN Model 2400 Perkin Elmer (Waltham, MA, USA) at Microanalytical Centre, Faculty of Science, Cairo University, Egypt. All the elemental analyses results corresponded to calculated values within experimental error. Progress of reactions was monitored by thin-layer chromatography (TLC) using precoated TLC sheets with Ultraviolet (UV) fluorescent silica gel (Merck 60F254), and spots were visualised by iodine vapours or irradiation with UV light (254&#x02009;nm). All chemicals were purchased from Sigma-Aldrich or Lancaster Synthesis Corporation (UK). Intermediates <bold>6&#x02013;8a&#x02013;i</bold> were prepared according to reported procedure<xref rid="CIT0047" ref-type="bibr"><sup>47</sup></xref><sup>,</sup><xref rid="CIT0048" ref-type="bibr"><sup>48</sup></xref>.</p><sec id="S0002-S2001-S3001" disp-level="3"><label>2.1.1.</label><title>General procedure for preparation of oxazolones (12a&#x02013;h)</title><p>A mixture of <italic>N</italic>-(3,4,5-trimethoxybenzoyl)glycine (0.30&#x02009;g, 1.10&#x02009;mmol) and the appropriate aldehydes <bold>8a&#x02013;h</bold> (1.00&#x02009;mmol) in acetic anhydride (1&#x02009;ml) and fused sodium acetate (0.1&#x02009;g, 1.2&#x02009;mmol) was heated on an oil bath at 80&#x02009;&#x000b0;C for 2&#x02009;h. After cooling down at room temperature the mixture was allowed to stand for 24&#x02009;h at 0&#x02009;&#x000b0;C. The precipitate was filtered off and washed three times with ice-cooled ethanol (10&#x02009;ml), and the product crystallised from ethanol.</p><sec id="S0002-S2001-S3001-S4001" disp-level="4"><label>2.1.1.1.</label><title>4-[(2-Methoxyquinolin-3-yl)methylene]-2&#x02013;(3,4,5-trimethoxyphenyl)oxazol-5(4H)-one (12a)</title><p>Yellow solid, Yield (81%); m.p. 215&#x02013;217&#x02009;&#x000b0;C. IR (KBr): &#x003c5;&#x02009;=&#x02009;1776 (C=O), 1621 (C=N), 1599 (C=C) cm<sup>&#x02212;1</sup>. <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4;: 9.48 (s, 1H, Ar-H), 7.86&#x02013;7.81 (m, 2H, Ar-H), 7.71&#x02013;7.67 (m, 2H, Ar-H), 7.45&#x02013;7.41 (m, 3H, Ar-H), 4.15 (s, 3H, OCH<sub>3</sub>), 4.00 (s, 9H, 3 OCH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4;: 167.1, 163.9, 160.0, 153.5, 147.1, 143.1, 142.4, 134.6, 131.5, 128.9, 127.1, 125.2, 124.7, 123.6, 120.1, 118.5, 105.8, 61.1, 56.4, 54.1&#x02009;ppm. MS (70&#x02009;eV): <italic>m/z</italic> (%): 420 (7.79) [M<sup>+</sup>]; Anal. Calcd for C<sub>23</sub>H<sub>20</sub>N<sub>2</sub>O<sub>6</sub>: C, 65.71; H, 4.80; N, 6.66. Found: C, 65.64; H, 4.74; N, 6.71</p></sec><sec id="S0002-S2001-S3001-S4002" disp-level="4"><label>2.1.1.2.</label><title>4-[(2-Methoxy-6-methylquinolin-3-yl)methylene]-2&#x02013;(3,4,5-trimethoxyphenyl) oxazol-5(4H)-one (12b)</title><p>Pale yellow solid, Yield (79%); m.p. 218&#x02013;220&#x02009;&#x000b0;C. <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4;: 9.36 (s, 1H, Ar-H), 7.72 (t, <italic>J</italic>&#x02009;=&#x02009;4&#x02009;Hz, 2H, Ar-H), 7.56 (s, 1H, Ar-H), 7.49 (d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, 1H, Ar-H), 7.41 (s, 2H, Ar-H), 4.11 (s, 3H, OCH<sub>3</sub>), 3.98 (d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, 9H, 3OCH<sub>3</sub>) and 2.51 (s, 3H, CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4;: 167.2, 163.8, 159.7, 153.5, 145.7, 143.1, 141.8, 134.4, 134.3, 133.6, 127.8, 126.9, 125.1, 124.1, 120.3, 118.1, 110.0, 105.7, 61.1, 56.4, 53.9, 21.3&#x02009;ppm. MS (70&#x02009;eV): <italic>m/z</italic> (%): 434 (9.79) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>22</sub>N<sub>2</sub>O<sub>6</sub>: C, 66.35; H, 5.10; N, 6.45. Found: C, 66.29; H, 5.04; N, 6.50.</p></sec><sec id="S0002-S2001-S3001-S4003" disp-level="4"><label>2.1.1.3.</label><title>4-[(2-Methoxy-7-methylquinolin-3-yl)methylene]-2&#x02013;(3,4,5-trimethoxyphenyl) oxazol-5(4H)-one (12c)</title><p>Yellow solid, Yield (84%); m.p. 233&#x02013;235&#x02009;&#x000b0;C. <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4;: 9.50 (s, 1H, Ar-H), 7.76&#x02013;7.73 (m, 3H, Ar-H),7.45 (s, 2H, Ar-H), 7.30&#x02013;7.28 (m, 1H, Ar-H), 4.20 (s, 3H, OCH<sub>3</sub>), 4.00 (d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, 9H, 3 OCH<sub>3</sub>), 2.58 (s, 3H, CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4;: 167.2, 163.8, 162.6, 160.2, 153.5, 143.1, 142.8, 142.5, 134.3, 128.7, 127.0, 126.3, 123.9, 123.1, 120.2, 117.6, 105.7, 61.1, 56.4, 54.6, 22.1&#x02009;ppm. MS (70&#x02009;eV): <italic>m/z</italic> (%): 434 (6.90) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>22</sub>N<sub>2</sub>O<sub>6</sub>: C, 66.35; H, 5.10; N, 6.45. Found: C, 66.32; H, 5.05; N, 6.47.</p></sec><sec id="S0002-S2001-S3001-S4004" disp-level="4"><label>2.1.1.4.</label><title>4-[(2-Methoxy-8-methylquinolin-3-yl)methylene]-2&#x02013;(3,4,5-trimethoxyphenyl) oxazol-5(4H)-one (12d)</title><p>Yellow solid, Yield (82%); m.p. 236&#x02013;238&#x02009;&#x000b0;C. <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4;: 9.44 (s, 1H, Ar-H), 7.73 (s, 1H, Ar-H), 7.64 (d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, 1H, Ar-H), 7.52 (d, <italic>J</italic>&#x02009;=&#x02009;6.40&#x02009;Hz, 1H, Ar-H), 7.39 (s, 2H, Ar-H), 7.32&#x02013;7.28 (m, 1H, Ar-H), 4.12 (s, 3H, OCH<sub>3</sub>), 3.98 (s, 9H, 3 OCH<sub>3</sub>), 2.68 (s, 3H, CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4;: 167.2, 163.8, 159.1, 153.7, 146.0, 143.1, 142.7, 135.4, 134.3, 131.6, 126.7, 125.0, 124.3, 124.0, 120.2, 118.0, 105.6, 61.1, 56.3, 53.7, 17.5&#x02009;ppm. MS (70&#x02009;eV): <italic>m/z</italic> (%): 434 (9.50) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>22</sub>N<sub>2</sub>O<sub>6</sub>: C, 66.35; H, 5.10; N, 6.45. Found: C, 66.30; H, 5.04; N, 6.51.</p></sec><sec id="S0002-S2001-S3001-S4005" disp-level="4"><label>2.1.1.5.</label><title>4-[2,6-Dimethoxyquinolin-3-yl)methylene]-2&#x02013;(3,4,5-trimethoxyphenyl)oxazol-5(4H)-one (12e)</title><p>Yellow solid, Yield (84%); m.p. 242&#x02013;244&#x02009;&#x000b0;C. 1784 (C=O), 1618 (C=N), 1586 (C=C) cm<sup>&#x02212;1</sup>. <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4;: 9.33 (s, 1H, Ar-H), 7.73 (d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, 2H, Ar-H), 7.42&#x02013;7.32 (m, 3H, Ar-H), 7.12 (s, 1H, Ar-H), 4.10 (s, 3H, OCH<sub>3</sub>), 3.99 (s, 9H, 3 OCH<sub>3</sub>) 3.93 (s, 3H, OCH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4;: 167.1, 163.8, 158.9, 156.4, 153.5, 143.2, 143.0, 141.1, 134.5, 128.5, 125.7, 124.2, 123.0, 120.2, 118.4, 107.4, 105.9, 61.2, 56.5, 55.6, 53.8&#x02009;ppm. MS (70&#x02009;eV): <italic>m/z</italic> (%): 450 (8.40) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>22</sub>N<sub>2</sub>O<sub>7</sub>: C, 64.00; H, 4.92; N, 6.22. Found: C, 63.94; H, 4.87; N, 6.28.</p></sec><sec id="S0002-S2001-S3001-S4006" disp-level="4"><label>2.1.1.6.</label><title>4-[(2,7-Dimethoxyquinolin-3-yl)methylene]-2&#x02013;(3,4,5-trimethoxyphenyl)oxazol-5(4H)-one (12f)</title><p>Yellow solid, Yield (84%); m.p. 221&#x02013;223&#x02009;&#x000b0;C. <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4;: 9.39 (s, 1H, Ar-H), 7.70&#x02013;7.66 (m, 2H, Ar-H), 7.38 (s, 2H, Ar-H), 7.16 (s, 1H, Ar-H), 7.04 (d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, 1H, Ar-H), 4.11 (s, 3H, OCH<sub>3</sub>), 3.97 (s, 9H, 3OCH<sub>3</sub>) 3.95 (s, 3H, OCH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4;: 167.4, 163.3, 162.8, 160.7, 153.5, 149.7, 142.8, 142.0, 133.3, 130.2, 124.4, 120.4, 120.1, 117.2, 115.9, 106.4, 105.5, 61.2, 56.2, 55.6, 53.9&#x02009;ppm. MS (70&#x02009;eV): <italic>m/z</italic> (%): 450 (7.30) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>22</sub>N<sub>2</sub>O<sub>7</sub>: C, 64.00; H, 4.92; N, 6.22. Found: C, 63.96; H, 4.96; N, 6.25.</p></sec><sec id="S0002-S2001-S3001-S4007" disp-level="4"><label>2.1.1.7.</label><title>4-[(7-Isopropoxy-2-methoxyquinolin-3-yl)methylene]-2&#x02013;(3,4,5-trimethoxy phenyl)oxazol-5(4H)-one (12g)</title><p>Yellow solid, Yield (77%); m.p. 227&#x02013;229&#x02009;&#x000b0;C. <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; ppm: 9.41 (s, 1H, Ar-H), 7.74&#x02013;7.67 (m, 2H, Ar-H), 7.41 (s, 2H, Ar-H),7.16&#x02013;7.00 (m, 2H, Ar-H), 4.87&#x02013;4.76 (m, 1H, OCH-), 4.12 (s, 3H, OCH<sub>3</sub>), 3.98 (s, 9H, 3 OCH<sub>3</sub>), 1.45 (d, <italic>J</italic>&#x02009;=&#x02009;4.0&#x02009;Hz, 6H, 2 CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4;: 167.4, 163.1, 161.2, 160.7, 153.5, 149.5, 142.9, 141.9, 133.2, 130.3, 124.6, 120.4, 119.9, 118.2, 115.7, 107.9, 105.5, 70.3, 61.3, 56.4, 53.9, 22.0&#x02009;ppm. MS (70&#x02009;eV): <italic>m/z</italic> (%): 478 (9.50) [M<sup>+</sup>]; Anal. Calcd for C<sub>26</sub>H<sub>26</sub>N<sub>2</sub>O<sub>7</sub>: C, 65.26; H, 5.48; N, 5.85. Found: C, 65.21; H, 5.45; N, 5.91.</p></sec><sec id="S0002-S2001-S3001-S4008" disp-level="4"><label>2.1.1.8.</label><title>4-[(7-(Benzyloxy)-2-methoxyquinolin-3-yl)methylene]-2&#x02013;(3,4,5-trimethoxy phenyl)oxazol-5(4H)-one (12h)</title><p>Pale yellow solid, Yield (73%); m.p. 247&#x02013;249&#x02009;&#x000b0;C. <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4;: 9.43 (s, 1H, Ar-H), 7.72 (t, <italic>J</italic>&#x02009;=&#x02009;8&#x02009;Hz, 2H, Ar-H), 7.51&#x02013;7.35 (m, 6H, Ar-H), 7.28&#x02013;7.26 (m, 2H, Ar-H), 7.14 (d, 1H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, 1H, Ar-H), 5.21 (s, 2H, OCH<sub>2</sub>&#x02212;), 4.12 (s, 3H, OCH<sub>3</sub>), 3.98 (s, 9H, 3 OCH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4;: 167.4, 163.3, 161.9, 160.8, 153.5, 149.4, 142.9, 141.9, 136.2, 133.5, 130.2, 128.7, 128.3, 127.7, 124.4, 120.4, 120.3, 117.5, 116.0, 107.5, 105.6, 70.3, 61.3, 56.4, 53.9&#x02009;ppm. MS (70&#x02009;eV): <italic>m/z</italic> (%): 526 (7.30) [M<sup>+</sup>]; Anal. Calcd for C<sub>30</sub>H<sub>26</sub>N<sub>2</sub>O<sub>7</sub>: C, 68.43; H, 4.98; N, 5.35. Found: C, 68.39; H, 4.92; N, 5.41.</p></sec></sec><sec id="S0002-S2001-S3002" disp-level="3"><label>2.1.2.</label><title><italic>General procedure for preparation of</italic> (13a&#x02013;h)</title><p>The appropriate oxazolones <bold>12a&#x02013;h</bold> (1&#x02009;mmol) was stirred and heated under reflux in ethanol (10&#x02009;ml) containing ammonium hydroxide (10&#x02009;ml), and the reaction monitored by TLC. After completion of the reaction in 24&#x02009;h, the solvent was concentrated and cooled, and the precipitate was filtered off and crystallised from ethanol.</p><sec id="S0002-S2001-S3002-S4001" disp-level="4"><label>2.1.2.1.</label><title>5-[(2-Methoxyquinolin-3-yl)methylene]-2&#x02013;(3,4,5-trimethoxyphenyl)-3,5-dihydro-4H-imidazol-4-one (13a)</title><p>Yellow solid, Yield (81%); m.p. 230&#x02013;232&#x02009;&#x000b0;C. IR (KBr): &#x003c5;&#x02009;=&#x02009;3222 (NH), 1709 (C=O), 1642 (C=N), 1615, 1589 (C=C) cm<sup>&#x02212;1</sup>. <sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>) &#x003b4;: 12.22 (s, 1H, exch., NH), 9.69 (s, 1H, Ar-H), 8.03 (d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, 1H, Ar-H), 7.80&#x02013;7.70 (m, 2H, Ar-H), 7.59 (s, 2H, Ar-H), 7.49 (t, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, 1H, Ar-H), 7.28 (s, 1H, Ar-H), 4.11 (s, 3H, OCH<sub>3</sub>), 3.94 (s, 6H, 2OCH<sub>3</sub>), 3.80 (s, 3H, OCH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>) &#x003b4;: 187.4, 165.0, 164.2, 161.3, 157.9, 153.5, 146.7, 140.9, 132.2, 128.9, 126.7, 125.2, 123.9, 118.4, 108.7, 104.2, 60.3, 56.3, 54.1&#x02009;ppm. MS (70&#x02009;eV): <italic>m/z</italic> (%): 419 (5.40) [M<sup>+</sup>]; Anal. Calcd for C<sub>23</sub>H<sub>21</sub>N<sub>3</sub>O<sub>5</sub>: C, 65.86; H, 5.05; N, 10.02. Found: C, 65.81; H, 4.99; N, 10.09.</p></sec><sec id="S0002-S2001-S3002-S4002" disp-level="4"><label>2.1.2.2.</label><title>5-[(2-Methoxy-6-methylquinolin-3-yl)methylene]-2&#x02013;(3,4,5-trimethoxyphenyl)-3,5-dihydro-4H-imidazol-4-one (13b)</title><p>Yellow solid, Yield (81%); m.p. 223&#x02013;225&#x02009;&#x000b0;C. <sup>1</sup>HNMR (400&#x02009;MHz, DMSO-d<sub>6</sub>) &#x003b4;: 12.18 (s, 1H, exch., NH), 9.55 (s, 1H, Ar-H), 7.74&#x02013;7.54 (m, 5H, Ar-H), 7.26&#x02013;7.24 (d, <italic>J</italic>&#x02009;=&#x02009;6.6&#x02009;Hz, 1H, Ar-H), 4.07 (s, 3H, OCH<sub>3</sub>), 3.93 (s, 6H, OCH<sub>3</sub>), 3.80 (s, 3H, OCH<sub>3</sub>), 2.47 (s, 3H, CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>) &#x003b4;: 172.0, 162.2, 156.0, 153.7, 144.6, 142.6, 142.4, 141.2, 134.4, 133.4, 128.1, 126.8, 125.4, 123.2, 119.3, 116.2, 110.0, 106.2, 60.7, 56.8, 54.2, 21.3&#x02009;ppm. MS (70&#x02009;eV): <italic>m/z</italic> (%): 433 (5.60) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>5</sub>: C, 66.50; H, 5.35; N, 9.69. Found: C, 66.41; H, 5.28; N, 9.75.</p></sec><sec id="S0002-S2001-S3002-S4003" disp-level="4"><label>2.1.2.3.</label><title>5-[(2-Methoxy-7-methylquinolin-3-yl)methylene]-2&#x02013;(3,4,5-trimethoxyphenyl)-3,5-dihydro-4H-imidazol-4-one (13c)</title><p>Yellow solid, Yield (84%); m.p. 236&#x02013;238&#x02009;&#x000b0;C. IR (KBr): &#x003c5;&#x02009;=&#x02009;3215 (NH), 1711 (C=O), 1639 (C=N), 1590 (C=C) cm<sup>&#x02212;1</sup>. <sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>) &#x003b4;: 12.17 (s, 1H, exch. NH), 9.63 (s, 1H, Ar-H), 7.92 (d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, 1H, Ar-H), 7.58 (s, 3H, Ar-H), 7.32 (d, <italic>J</italic>&#x02009;=&#x02009;8&#x02009;Hz, 1H, Ar-H), 7.27 (s, 1H, Ar-H), 4.09 (s, 3H, OCH<sub>3</sub>), 3.94 (s, 6H, 2OCH<sub>3</sub>), 3.80 (s, 3H, OCH<sub>3</sub>), 2.53 (s, 3H, CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>) &#x003b4;: 162.6, 162.5, 160.3, 153.9, 142.2, 141.5, 129.1, 127.1, 126.3, 123.6, 118.3, 115.8, 105.6, 60.8, 56.5, 54.2, 22.0&#x02009;ppm. MS (70&#x02009;eV): <italic>m/z</italic> (%): 433 (8.40) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>5</sub>: C, 66.50; H, 5.35; N, 9.69. Found: C, 66.44; H, 5.32; N, 9.72.</p></sec><sec id="S0002-S2001-S3002-S4004" disp-level="4"><label>2.1.2.4.</label><title>5-[(2-Methoxy-8-methylquinolin-3-yl)methylene]-2&#x02013;(3,4,5-trimethoxy phenyl)-3,5-dihydro-4H-imidazol-4-one (13d)</title><p>Yellow solid, Yield (82%); m.p. 233&#x02013;235&#x02009;&#x000b0;C. <sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>) &#x003b4;: 12.16 (s, 1H, exch., NH), 9.59 (s, 1H, Ar-H), 7.80 (s, 1H, Ar-H), 7.70 (d, <italic>J</italic>&#x02009;=&#x02009;8&#x02009;Hz, 1H, Ar-H), 7.59&#x02013;7.56 (m, 3H, Ar-H), 7.29 (s, 1H, Ar-H), 4.10 (s, 3H, OCH<sub>3</sub>), 3.95 (s, 6H, 2OCH<sub>3</sub>), 3.80 (s, 3H, OCH<sub>3</sub>), 2.49 (s, 3H, CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>) &#x003b4;: 161.9, 158.2, 153.3, 142.2, 141.6, 141.5, 134.2, 131.3, 126.7, 124.8, 124.5, 118.6, 115.4, 105.3, 60.2, 56.1, 53.5, 17.1&#x02009;ppm. MS (70&#x02009;eV): <italic>m/z</italic> (%): 433 (7.12) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>5</sub>: C, 66.50; H, 5.35; N, 9.69. Found: C, 66.47; H, 5.30; N, 9.73.</p></sec><sec id="S0002-S2001-S3002-S4005" disp-level="4"><label>2.1.2.5.</label><title>5-[(2,6-Dimethoxyquinolin-3-yl)methylene]-2&#x02013;(3,4,5-trimethoxyphenyl)-3,5-dihydro-4H-imidazol-4-one (13e)</title><p>Yellow solid, Yield (84%); m.p. 253&#x02013;255&#x02009;&#x000b0;C. <sup>1</sup>HNMR (400&#x02009;MHz, DMSO-d<sub>6</sub>) &#x003b4;: 12.03 (s, 1H, exchangeable, NH), 9.50 (s, 1H, Ar-H), 7.83&#x02013;7.77 (m, 1H, Ar-H), 7.53 (s, 2H, Ar-H), 7.48 (s, 1H, Ar-H), 7.20&#x02013;7.05 (m, 2H, Ar-H), 4.04 (s, 3H, OCH<sub>3</sub>), 3.90 (s, 9H, 3 OCH<sub>3</sub>), 3.79 (s, 3H, OCH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>) &#x003b4;: 164.6, 161.9, 157.1, 156.9, 154.1, 142.8, 141.9, 140.0, 128.4, 125.1, 124.1, 118.9, 110.0, 109.3, 108.0, 105.3, 60.7, 57.0, 56.2, 54.4&#x02009;ppm. MS (70&#x02009;eV): <italic>m/z</italic> (%): 449 (8.35) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>6</sub>: C, 64.16; H, 5.16; N, 9.35. Found: C, 64.11; H, 5.12; N, 9.31.</p></sec><sec id="S0002-S2001-S3002-S4006" disp-level="4"><label>2.1.2.6.</label><title>5-[(2,7-Dimethoxyquinolin-3-yl)methylene]-2&#x02013;(3,4,5-trimethoxyphenyl)-3,5-dihydro-4H-imidazol-4-one (13f)</title><p>Yellow solid, Yield (86%); m.p. 241&#x02013;243&#x02009;&#x000b0;C. <sup>1</sup>HNMR (400&#x02009;MHz, DMSO-d<sub>6</sub>) &#x003b4;: 12.10 (s, 1H, exch., NH), 9.57 (s, 1H, Ar-H), 7.86 (d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, 1H, Ar-H), 7.53 (s, 2H, Ar-H), 7.23 (s, 1H, Ar-H), 7.15&#x02013;7.08 (m, 2H, Ar-H), 4.07 (s, 3H, OCH<sub>3</sub>), 3.92 (s, 6H, 2OCH<sub>3</sub>), 3.79 (s, 3H, OCH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>) &#x003b4;: 163.9, 162.6, 161. 5, 158.3, 153.3, 149.0, 140.7, 140.3, 129.9, 118.7, 118.2, 117.4, 106.3, 105.7, 104.1, 60.1, 56.3, 55.7, 54.1&#x02009;ppm. MS (70&#x02009;eV): <italic>m/z</italic> (%): 449 (5.65) [M<sup>+</sup>]; Anal. Calcd for C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>6</sub>: C, 64.16; H, 5.16; N, 9.35. Found: C, 64.13; H, 5.10; N, 9.29.</p></sec><sec id="S0002-S2001-S3002-S4007" disp-level="4"><label>2.1.2.7.</label><title>5-((7-Isopropoxy-2-methoxyquinolin-3-yl)methylene)-2&#x02013;(3,4,5-trimethoxy phenyl)-3,5-dihydro-4H-imidazol-4-one (13g)</title><p>Yellow solid, Yield (77%); m.p. 238&#x02013;240&#x02009;&#x000b0;C. <sup>1</sup>HNMR (400&#x02009;MHz, DMSO-d<sub>6</sub>) &#x003b4;: 12.19 (s, 1H, exch.,NH), 9.61 (s, 1H, Ar-H), 7.92 (d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, 1H, Ar-H), 7.58 (s, 2H, Ar-H), 7.28 (s, 1H, Ar-H), 7.17 (s, 1H, Ar-H), 7.09&#x02013;7.07 (d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, 1H, Ar-H), 4.90&#x02013;4.83 (m, 1H, OCH), 4.09 (s, 3H, OCH<sub>3</sub>), 3.94 (s, 6H, 2OCH<sub>3</sub>), 3.79 (s, 3H, OCH<sub>3</sub>), 1.37 (s, 3H, CH<sub>3</sub>) 1.36 (s, 3H, CH<sub>3</sub>) ppm. <sup>13</sup>C NMR (100&#x02009;MHz, DMSO<italic>-</italic>d<sub>6</sub>) &#x003b4;: 164.2, 161.3, 156.7, 154.2, 153.5, 142.0, 140.9, 139.7, 128.1, 124.8, 122.4, 118.6, 109.2, 108.5, 104.3, 69.8, 60.3, 56.3, 53.9, 21.7&#x02009;ppm. MS (70&#x02009;eV): <italic>m/z</italic> (%): 477 (9.25) [M<sup>+</sup>]; Anal. Calcd for C<sub>26</sub>H<sub>27</sub>N<sub>3</sub>O<sub>6</sub>: C, 65.40; H, 5.70; N, 8.80. Found: C, 65.35; H, 5.66; N, 8.86.</p></sec><sec id="S0002-S2001-S3002-S4008" disp-level="4"><label>2.1.2.8.</label><title>5-[(7-(Benzyloxy)-2-methoxyquinolin-3-yl)methylene]-2&#x02013;(3,4,5-trimethoxy phenyl)-3,5-dihydro-4H-imidazol-4-one (13h)</title><p>Yellow solid, Yield (73%); m.p. 259&#x02013;261&#x02009;&#x000b0;C. <sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>) &#x003b4;: 12.16 (s, 1H, exch., NH), 9.62 (s, 1H, Ar-H), 7.96&#x02013;7.94 (d, <italic>J</italic>&#x02009;=&#x02009;8&#x02009;Hz, 1H, Ar-H), 7.58&#x02013;7.28 (m, 10H, ArH), 5.30 (s, 2H, OCH<sub>2</sub>-), 4.09 (s, 3H, OCH<sub>3</sub>), 3.94 (s, 6H, 2OCH<sub>3</sub>), 3.79 (s, 3H, OCH<sub>3</sub>) ppm. <sup>13</sup>C NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>) &#x003b4;: 163.9, 161.6, 158.5, 153.5, 148.8, 140.7, 140.3, 136.6, 130.2, 128.5, 128.0, 127.8, 118.9, 118.5, 117.8, 107.2, 105.9, 104.0, 69.7, 60.4, 56.3, 54.0&#x02009;ppm. MS (70&#x02009;eV): <italic>m/z</italic> (%): 525 (6.75) [M<sup>+</sup>]; Anal. Calcd for C<sub>30</sub>H<sub>27</sub>N<sub>3</sub>O<sub>6</sub>: C, 68.56; H, 5.18; N, 8.00. Found: C, 68.51; H, 5.13; N, 8.05.</p></sec></sec></sec><sec id="S0002-S2002" disp-level="2"><label>2.2.</label><title>Biochemical evaluation of activity</title><p>All biochemical assays were performed in triplicate on at least three independent occasions for the determination of mean values.</p><sec id="S0002-S2002-S3001" disp-level="3"><label>2.2.1.</label><title>Cell culture</title><p>The four human tumour cell lines MCF-7, HCT-116, HL-60 and HeLa used in this study were obtained from the VACSERA (Giza, Egypt) cell culture unit that were originally acquired from ATCC (Manassas, VA, USA). All the human tumour cell lines were cultured in Dulbecco&#x02019;s Modified Eagle&#x02019;s Medium (DMEM) with 10% foetal bovine serum, 2&#x02009;mM L-glutamine and 100&#x02009;&#x000b5;g/mL penicillin/streptomycin. Cells were maintained at 37&#x002da;C in 5% CO<sub>2</sub> in a humidified incubator. All cells were sub-cultured 3 times/week by trypsinisation using TrypLE Express (1X).</p></sec><sec id="S0002-S2002-S3002" disp-level="3"><label>2.2.2.</label><title>Cell viability assay</title><p>The quinoline compounds were evaluated for antiproliferative effect using the MTT viability assay of four cancer cell lines (MCF-7, HCT-116, HL-60 and HeLa) and normal breast cells MCF-10A to calculate the relative IC<sub>50</sub> values for each compound. Cells were seeded in triplicate in 96-well plates at a density of 10 &#x000d7; 10<sup>3</sup> cells/ml in a total volume of 200&#x02009;&#x000b5;l per well. 0.1% of DMSO was used as a vehicle control. Following, the cells were treated with 2&#x02009;&#x000b5;l test compound (from stock solutions in ethanol) to furnish the concentration range of study, 1&#x02009;nM to 50&#x02009;&#x000b5;M, and re-incubated for a further 72&#x02009;h. The culture medium was then removed, and the cells washed with 100&#x02009;&#x000b5;L phosphate buffered saline (PBS) and 50&#x02009;&#x000b5;L MTT added, to reach a final concentration of 1&#x02009;mg/mL. Cells were incubated for 2&#x02009;h in darkness at 37&#x02009;&#x000b0;C. Solubilisation was begun through the addition of 200&#x02009;ml DMSO, and the cells maintained at room temperature in darkness for 20&#x02009;min to ensure thorough colour diffusion before reading the absorbance. Plates were incubated for 72&#x02009;h at 37&#x02009;&#x000b0;C&#x02009;+&#x02009;5% CO<sub>2</sub>. The MTT (5&#x02009;mg/mL in PBS) was added and incubated for another 4&#x02009;h, and the optical density was detected with a microplate reader at 570&#x02009;nm. Results were expressed as percentage viability relative to vehicle control (100%). Dose response curves were plotted and IC<sub>50</sub> values (concentration of drug resulting in 50% reduction in cell survival) were obtained using the commercial software package Prism (GraphPad Software, Inc., La Jolla, CA, USA). All the experiments were repeated in at least three independent experiments.</p></sec><sec id="S0002-S2002-S3003" disp-level="3"><label>2.2.3.</label><title>Tubulin polymerisation assay</title><p>The assembly of purified bovine tubulin was monitored using a kit, BK006, purchased from Cytoskeleton Inc., (Denver, CO, USA). The assay was carried out in accordance with the manufacturer&#x02019;s instructions using the standard assay conditions<xref rid="CIT0049" ref-type="bibr"><sup>49</sup></xref>. Briefly, purified (&#x0003e;99%) bovine brain tubulin (3&#x02009;mg/mL) in a buffer consisting of 80&#x02009;mM PIPES (pH 6.9), 0.5&#x02009;mM EGTA, 2&#x02009;mM MgCl<sub>2</sub>, 1&#x02009;mM GTP and 10% glycerol was incubated at 37&#x02009;&#x000b0;C in the presence of either vehicle (2% (v/v) ddH<sub>2</sub>O), CA-4, or the quinoline compounds. Light is scattered proportionally to the concentration of polymerised microtubules in the assay. Therefore, tubulin assembly was monitored turbidimetrically at 340&#x02009;nm in a Spectramax 340&#x02009;PC spectrophotometer (Molecular Devices, Sunnyvale, CA, USA). The concentration that inhibits tubulin polymerisation by 50% (IC<sub>50</sub>) was determined using area under the curve (AUC). The AUC of the untreated controls were considered as 100% polymerisation. The IC<sub>50</sub> value for each compound was computed using GraphPad Prism Software.</p></sec><sec id="S0002-S2002-S3004" disp-level="3"><label>2.2.4.</label><title>Colchicine site competitive binding assay</title><p>The affinity of compounds <bold>12c</bold> to colchicine binding site was determined using Colchicine Site Competitive Assay kit CytoDYNAMIX Screen15 (Cytoskeleton, Inc., Denver, CO, USA) using the standard protocol of the manufacturer to determine Ki. Biotin-labelled tubulin (0.5&#x02009;&#x000b5;g) in 10&#x02009;&#x000b5;L of reaction buffer was mixed with [3H]colchicine (0.08&#x02009;&#x000b5;M, PerkinElmer, Waltham, MA) and the test compounds (positive control colchicine, negative control vinblastine, G-1, fluorescent G-1, or 2-ME) in a 96-well plate (final volume: 100&#x02009;&#x000b5;L). After incubating for 2&#x02009;h at 37&#x02009;&#x000b0;C with gentle shaking, streptavidin-labelled yttrium SPA beads (80&#x02009;&#x000b5;g in 20&#x02009;&#x000b5;L reaction buffer, PerkinElmer, Waltham, MA) were added to each well and incubated for 30&#x02009;min at 4&#x02009;&#x000b0;C. The plates were then read on a scintillation counter (Packard Instrument, Topcount Microplate Reader) and the percentage of inhibition was calculated<xref rid="CIT0050" ref-type="bibr"><sup>50</sup></xref><sup>,</sup><xref rid="CIT0051" ref-type="bibr"><sup>51</sup></xref>.</p></sec><sec id="S0002-S2002-S3005" disp-level="3"><label>2.2.5.</label><title>Cell cycle analysis</title><p>MCF-7 cells were seeded at a density of 1&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells/well in 6-well plates and treated with CA-4 (50&#x02009;nM) and compound <bold>12c</bold> (50 and 250&#x02009;nM) for 24, 48 and 72&#x02009;h. The cells were collected by trypsinisation and centrifuged at 800&#x000d7;<italic>g</italic> for 15&#x02009;min. Cells were washed twice with ice-cold PBS and fixed in ice-cold 70% ethanol overnight at &#x02212;20&#x02009;&#x000b0;C. Fixed cells were centrifuged at 800&#x000d7;<italic>g</italic> for 15&#x02009;min and stained with 50&#x02009;&#x000b5;g/mL of PI, containing 50&#x02009;&#x000b5;g/mL of DNase-free RNase A, at 37&#x02009;&#x000b0;C for 30&#x02009;min. The DNA content of cells (10,000 cells/experimental group) was analysed by flow cytometer at 488&#x02009;nm using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) and all data were recorded and analysed using the CellQuest Software (Becton-Dickinson).</p></sec><sec id="S0002-S2002-S3006" disp-level="3"><label>2.2.6.</label><title>Annexin V/PI apoptotic assay</title><p>Apoptotic cell death was detected by flow cytometry using Annexin V and propidium iodide (PI). MCF-7 Cells were seeded in 6 well plated at density of 1 &#x000d7; 10<sup>5</sup> cells/mL and treated with vehicle (0.1% (v/v) EtOH), positive control (CA-4) or compound <bold>12c</bold> (50 and 250&#x02009;nM) for 24, 48 and 72&#x02009;h. Cells were then harvested and prepared for flow cytometric analysis. Cells were washed in 1X binding buffer (20X binding buffer: 0.1&#x02009;M HEPES, pH 7.4; 1.4&#x02009;M NaCl; 25&#x02009;mM CaCl<sub>2</sub> diluted in dH<sub>2</sub>O) and incubated in the dark for 30&#x02009;min on ice in Annexin V-containing binding buffer [1:100]. Cells were then washed once in binding buffer and then re-suspended in PI-containing binding buffer [1:1000]. Samples were analysed immediately using the BD accuri flow cytometer and prism software for analysis the data. Four populations are produced during the assay Annexin V and PI negative (Q4, healthy cells), Annexin V positive and PI negative (Q3, early apoptosis), Annexin V and PI positive (Q2, late apoptosis) and Annexin V negative and PI positive (Q1, necrosis).</p></sec><sec id="S0002-S2002-S3007" disp-level="3"><label>2.2.7.</label><title>Evaluation of expression levels of anti-apoptotic proteins bcl-2, pro-apoptotic proteins bax and caspase 9</title><p>The level of the anti-apoptotic marker and apoptotic marker BAX were assessed using Bcl-2 Elisa kit and human Bax ELISA Kit purchased from Zymed laboratories, invitrogen and Cloud-Clone Crop. (Katy, TX, USA), respectively, following the manufacturer&#x02019;s instructions. Briefly, Treated MCF-7 cell lysate with 250&#x02009;nM of compound <bold>12c</bold> were prepared, and equal amount of cell lysates were loaded and propped with specific antibodies. The samples were measured and analysed at 450&#x02009;nm in ROBONEK P2000 ELISA reader<xref rid="CIT0052" ref-type="bibr"><sup>52</sup></xref>. <italic>In&#x000a0;Vitro</italic> Caspase-9 Activation Assay was performed using human active caspase-9 Invitrogen EIA kit according to the manufacturer&#x02019;s instructions. Compound <bold>12c</bold> at concentrations of 50 and 250&#x02009;nM and CA-4 (50&#x02009;nM) were prepared in dH<sub>2</sub>O up to a final volume of 50&#x02009;&#x000b5;L/well followed by addition of 5&#x02009;&#x000b5;L of active caspase-9. Following, the cells were mixed and 50&#x02009;&#x000b5;L of the Master Mix was added to each well and allowed to react at 37&#x02009;&#x000b0;C for 1&#x02009;h. The fluorescence intensity of the test samples was recorded and analysed in a fluorescence plate reader at 400&#x02009;nm excitation and 505&#x02009;nm emissions. All experiments were conducted in triplicates.</p></sec><sec id="S0002-S2002-S3008" disp-level="3"><label>2.2.8.</label><title>Colony formation assay</title><p>MCF-7 cells (600 cells per well) were seeded in 6-well plates and incubated for 24&#x02009;h before being then treated with different doses of the compound <bold>12c</bold> (50 and 250&#x02009;nM) for 14&#x02009;days. Following, the cells were washed with PBS twice and subsequently fixed with 4% paraformaldehyde and stained with 0.05% crystal violet for 30&#x02009;min. Finally, cells were visualised using an inverted microscope.</p></sec><sec id="S0002-S2002-S3009" disp-level="3"><label>2.2.9.</label><title>Wound healing assay</title><p>MCF-7 were grown in 6-well plates for 24&#x02009;h, and scratches were made using pipette tip and washed with PBS to remove non-adherent cell debris. Subsequently, the cells were treated with different concentrations of <bold>12c</bold> for 24&#x02009;h. The migrations across the wound area were photographed under a phase contrast microscopy.</p></sec><sec id="S0002-S2002-S3010" disp-level="3"><label>2.2.10.</label><title>Measurement of mitochondrial depolarisation effect (&#x00394;&#x003c8;<sub>mt</sub>) and ROS levels in cells</title><p>Mitochondrial membrane potential (&#x00394;&#x003c8;<sub>mt</sub>) was measured by flow cytometry with DiOC2(3) staining and additional labelling with an annexin V conjugate. After treatment with compound <bold>12c</bold> (50 and 250&#x02009;nM) and CA-4 (50&#x02009;nM), cells were stained with DiOC2(3) dye for 30&#x02009;min in the incubator, then harvested and washed with PBS. DiOC2(3)-stained cells were resuspended with 1X annexin binding buffer, followed by addition of annexin V conjugate and incubated at 37&#x02009;&#x000b0;C for 15&#x02009;min. The data from the flow cytometry were analysed by Cell Quest software. Production of intracellular reactive oxygen species (ROS) was measured using 2,7&#x02013;dichlorofluorescin diacetate (H<sub>2</sub>-DCFDA) dye. MCF-7 cells were seeded and treated either with vehicle (0.1% DMSO) or with compound <bold>12c</bold> (50 and 250&#x02009;nM) or CA-4 (50&#x02009;nM) for 6, 12 and 24&#x02009;h. H<sub>2</sub>O<sub>2</sub> was used as a positive control. The amount of ROS generated was estimated after 2&#x02009;h of selected compound treatment. The cells were collected by centrifugation and washed twice with PBS. Cells were then incubated with DCFDA dye (25&#x02009;&#x000b5;M) in dark at 37&#x02009;&#x000b0;C for 1&#x02009;h. Fluorescence spectra (510&#x02009;&#x02212;&#x02009;600&#x02009;nm) were monitored using an excitation wavelength of 488&#x02009;nm<xref rid="CIT0053" ref-type="bibr"><sup>53</sup></xref><sup>,</sup><xref rid="CIT0054" ref-type="bibr"><sup>54</sup></xref>.</p></sec></sec></sec><sec sec-type="results" id="S0003" disp-level="1"><label>3.</label><title>Results and discussion</title><sec id="S0003-S2001" disp-level="2"><label>3.1.</label><title>Design and chemistry</title><p>The natural product, Combretastatin A-4 (CA-4; <xref ref-type="fig" rid="F0001">Figure 1</xref>) exhibits significant antiproliferative activities against several tumour cells by binding to the colchicine site of tubulin to inhibit the protein polymerisation<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>. However, the <italic>cis</italic> double bond of CA-4 has a propensity to isomerise into the inactive <italic>trans</italic> configuration, leading to reduction in the molecule&#x02019;s pharmacologic activity. Several structural modifications of the CA-4 pharmacophore have subsequently been undertaken to overcome this disadvantage, e.g. replacing the <italic>cis</italic> double bond with a heterocycle, oxadiazole, isoxazole and imidazole, resulting in compounds, such as <bold>1</bold>, <bold>2</bold> and <bold>3</bold> respectively (<xref ref-type="fig" rid="F0001">Figure 1</xref>)<xref rid="CIT0027" ref-type="bibr"><sup>27&#x02013;32</sup></xref>. In this work, we undertook a rational design approach of introducing chalcone system (ring C) in the form of either oxazolone or imidazolone between the two rings A and B, as well as isosterically replace ring B with quinolone. Specifically, the rigidity of the molecules was increased by introducing 1,3-oxazol-5-ones and 1,3-imidazol-4-ones to the <italic>cis-</italic>olefinic bond of CA-4, which we anticipate would create a desirable conformational and configurational restriction to prevent isomerisation of CA-4 into the inactive <italic>trans</italic>-isomer, as well as improve on the anticancer activities of these compounds since chalcones are well known for their anticancer properties<xref rid="CIT0055" ref-type="bibr"><sup>55</sup></xref><sup>,</sup><xref rid="CIT0056" ref-type="bibr"><sup>56</sup></xref>. The second design step involves varying the electronic substituents effect on the quinolyl moiety (ring B), while maintaining the natural active compound 3,4,5-trimethoxyphenyl moiety, which we anticipate will increase the potency of these compounds.</p><p>The syntheses of the proposed quinoline compounds <bold>12a&#x02013;h</bold> (oxazolones) and <bold>13a&#x02013;h (</bold>imidazolones) (<xref rid="t0001" ref-type="table">Table 1</xref>) are shown in <xref ref-type="scheme" rid="SCH001 SCH002">Schemes 1 and 2</xref> and involve two core structural components: (i) 2-methoxyquinolyl-3-carbaldehyde nucleus <bold>8a&#x02013;h</bold>, and (ii) 3,4,5-trimethoxyphenyl moiety <bold>11</bold>. A concise (three-step) synthesis was used for the synthesis of the first core structure, 2-methoxyquinoline-3-carbaldehyde derivatives <bold>8a&#x02013;h,</bold> as shown in <xref ref-type="scheme" rid="SCH001">Scheme 1</xref>. The synthesis was initiated with acetylation of the starting aniline derivatives <bold>5a&#x02013;h</bold> using acetic anhydride and glacial acetic acid at 0&#x02009;&#x000b0;C. The produced amides <bold>6a&#x02013;h</bold> were subjected to Vilsmeier&#x02013;Haack reaction to give the corresponding quinoline-3-aldehyde derivatives <bold>7a&#x02013;h</bold>. Addition of methoxy substituent to <bold>7a&#x02013;h</bold> to give <bold>8a&#x02013;h</bold> was achieved through the use of sodium methoxide at 40&#x02009;&#x000b0;C in methanol<xref rid="CIT0047" ref-type="bibr"><sup>47</sup></xref><sup>,</sup><xref rid="CIT0048" ref-type="bibr"><sup>48</sup></xref>. The synthesis of the second core 3,4,5-trimethoxyphenyl moiety <bold>11</bold> started with acylation of the acid <bold>9</bold> under highly acidic condition using SOCl<sub>2</sub> to give acyl benzotriazole <bold>10</bold> (<xref ref-type="scheme" rid="SCH002">Scheme 2</xref>)<xref rid="CIT0057" ref-type="bibr"><sup>57</sup></xref><sup>,</sup><xref rid="CIT0058" ref-type="bibr"><sup>58</sup></xref>. Following, treatment of the acyl benzotriazole <bold>10</bold> with glycine in aqueous acetonitrile gave the acyl glycine <bold>11</bold>. Condensation of <bold>11</bold> with the appropriate quinoline aldehydes <bold>8a&#x02013;h</bold> in the presence of acetic anhydride and catalytic amount of sodium acetate resulted in the formation of the oxazolones <bold>12a&#x02013;h</bold>. Aminolysis of <bold>12a&#x02013;h</bold> via condensation reaction with ammonia led to the formation of the imidazolones <bold>13a&#x02013;h</bold>. It seems the nucleophilic ammonia attacks the carbonyl group of the oxazolone ring, followed by immediate intramolecular condensation and cyclisation to give the imidazolones <bold>13a&#x02013;h</bold>. In summary, two classes of compounds, <bold>12a&#x02013;h</bold> (oxazolones) and <bold>13a&#x02013;h</bold> (imidazolones) were synthesised and used for further functional and biological studies.</p><fig id="SCH001" orientation="portrait" position="float"><label>Scheme 1.</label><caption><p>Synthetic route for preparation of aldehydes <bold>8a&#x02013;h</bold>. Reagents and conditions: (i) Ac<sub>2</sub>O, AcOH, 0&#x02009;&#x000b0;C,1h; (ii) DMF, POCl<sub>3</sub>, 70&#x02013;90&#x02009;&#x000b0;C, 18h; (iii) CH<sub>3</sub>ONa, MeOH, 40&#x02009;&#x000b0;C, 3&#x02013;6h.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1899168_SCH0001_C"/></fig><fig id="SCH002" orientation="portrait" position="float"><label>Scheme 2.</label><caption><p>Synthetic route for preparation of Quinoline targets <bold>12a&#x02013;h</bold> and <bold>13a&#x02013;h</bold>. Reagents and conditions: (i) SOCl<sub>2</sub>,DCM, r.t; (ii) TEA, MeCN,H<sub>2</sub>O, r.t; (iii) AcONa, AC<sub>2</sub>O, 80&#x02009;&#x000b0;C, 2h; (iv) NH<sub>4</sub>OH, EtOH, reflux, 18h.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1899168_SCH0002_C"/></fig><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Antiproliferative activity of quinoline analogues against human cancer cell lines (IC<sub>50</sub> [&#x000b5;M]). <inline-graphic xlink:href="IENZ_A_1899168_ILG0001_C.jpg" content-type="color"/></p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th rowspan="2" align="left">Compound number</th><th rowspan="2" align="center">X</th><th rowspan="2" align="center">R</th><th colspan="4" align="center">IC<sub>50</sub> value (&#x000b5;M)<sup>a</sup><hr/></th></tr><tr><th align="center">HL-60</th><th align="center">MCF-7</th><th align="center">HCT-116</th><th align="center">HeLa</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>12a</bold></td><td align="left">O</td><td align="left">H</td><td align="char" char=".">3.309&#x02009;&#x000b1;&#x02009;0.022</td><td align="left">1.712&#x02009;&#x000b1;&#x02009;0.040</td><td align="left">2.012&#x02009;&#x000b1;&#x02009;0.080</td><td align="left">2.113&#x02009;&#x000b1;&#x02009;0.034</td></tr><tr><td align="left"><bold>12b</bold></td><td align="left">O</td><td align="left">6-CH<sub>3</sub></td><td align="char" char=".">0.197&#x02009;&#x000b1;&#x02009;0.041</td><td align="left">0.132&#x02009;&#x000b1;&#x02009;0.013</td><td align="left">0.184&#x02009;&#x000b1;&#x02009;0.007</td><td align="left">0.117&#x02009;&#x000b1;&#x02009;0.085</td></tr><tr><td align="left"><bold>12c</bold></td><td align="left">O</td><td align="left">7-CH<sub>3</sub></td><td align="char" char=".">0.019&#x02009;&#x000b1;&#x02009;0.059</td><td align="left">0.010&#x02009;&#x000b1;&#x02009;0.003</td><td align="left">0.022&#x02009;&#x000b1;&#x02009;0.001</td><td align="left">0.042&#x02009;&#x000b1;&#x02009;0.001</td></tr><tr><td align="left"><bold>12d</bold></td><td align="left">O</td><td align="left">8-CH<sub>3</sub></td><td align="char" char=".">0.268&#x02009;&#x000b1;&#x02009;0.093</td><td align="left">0.154&#x02009;&#x000b1;&#x02009;0.071</td><td align="left">0.191&#x02009;&#x000b1;&#x02009;0.001</td><td align="left">0.153&#x02009;&#x000b1;&#x02009;0.083</td></tr><tr><td align="left"><bold>12e</bold></td><td align="left">O</td><td align="left">6-OCH<sub>3</sub></td><td align="char" char=".">0.068&#x02009;&#x000b1;&#x02009;0.034</td><td align="left">0.056&#x02009;&#x000b1;&#x02009;0.027</td><td align="left">0.031&#x02009;&#x000b1;&#x02009;0.001</td><td align="left">0.010&#x02009;&#x000b1;&#x02009;0.004</td></tr><tr><td align="left"><bold>12f</bold></td><td align="left">O</td><td align="left">7-OCH<sub>3</sub></td><td align="char" char=".">0.352&#x02009;&#x000b1;&#x02009;0.021</td><td align="left">0.052&#x02009;&#x000b1;&#x02009;0.0021</td><td align="left">0.066&#x02009;&#x000b1;&#x02009;0.005</td><td align="left">0.138&#x02009;&#x000b1;&#x02009;0.026</td></tr><tr><td align="left"><bold>12g</bold></td><td align="left">O</td><td align="left">7-OCH(CH<sub>3</sub>)<sub>2</sub></td><td align="char" char=".">1.822&#x02009;&#x000b1;&#x02009;0.640</td><td align="left">1.507&#x02009;&#x000b1;&#x02009;0.220</td><td align="left">7.880&#x02009;&#x000b1;&#x02009;0.300</td><td align="left">1.747&#x02009;&#x000b1;&#x02009;0.500</td></tr><tr><td align="left"><bold>12h</bold></td><td align="left">O</td><td align="left">7-OCH<sub>2</sub>Ph</td><td align="char" char=".">4.660&#x02009;&#x000b1;&#x02009;0.260</td><td align="left">1.932&#x02009;&#x000b1;&#x02009;0.612</td><td align="left">1.563&#x02009;&#x000b1;&#x02009;0.720</td><td align="left">1.054&#x02009;&#x000b1;&#x02009;0.840</td></tr><tr><td align="left"><bold>13a</bold></td><td align="left">NH</td><td align="left">H</td><td align="char" char=".">1.561&#x02009;&#x000b1;&#x02009;0.055</td><td align="left">1.033&#x02009;&#x000b1;&#x02009;0.055</td><td align="left">8.21&#x02009;&#x000b1;&#x02009;0.0077</td><td align="left">1.409&#x02009;&#x000b1;&#x02009;0.096</td></tr><tr><td align="left"><bold>13b</bold></td><td align="left">NH</td><td align="left">6-CH<sub>3</sub></td><td align="char" char=".">0.240&#x02009;&#x000b1;&#x02009;0.012</td><td align="left">0.063&#x02009;&#x000b1;&#x02009;0.0011</td><td align="left">0.173&#x02009;&#x000b1;&#x02009;0.025</td><td align="left">0.188&#x02009;&#x000b1;&#x02009;0.013</td></tr><tr><td align="left"><bold>13c</bold></td><td align="left">NH</td><td align="left">7-CH<sub>3</sub></td><td align="char" char=".">0.661&#x02009;&#x000b1;&#x02009;0.026</td><td align="left">0.223&#x02009;&#x000b1;&#x02009;0.056</td><td align="left">0.284&#x02009;&#x000b1;&#x02009;0.083</td><td align="left">0.733&#x02009;&#x000b1;&#x02009;0.091</td></tr><tr><td align="left"><bold>13d</bold></td><td align="left">NH</td><td align="left">8-CH<sub>3</sub></td><td align="char" char=".">0.096&#x02009;&#x000b1;&#x02009;0.006</td><td align="left">0.137&#x02009;&#x000b1;&#x02009;0.023</td><td align="left">0.109&#x02009;&#x000b1;&#x02009;0.011</td><td align="left">0.126&#x02009;&#x000b1;&#x02009;0.044</td></tr><tr><td align="left"><bold>13e</bold></td><td align="left">NH</td><td align="left">6-OCH<sub>3</sub></td><td align="char" char=".">0.272&#x02009;&#x000b1;&#x02009;0.050</td><td align="left">0.042&#x02009;&#x000b1;&#x02009;0.0025</td><td align="left">0.085&#x02009;&#x000b1;&#x02009;0.003</td><td align="left">0.062&#x02009;&#x000b1;&#x02009;0.003</td></tr><tr><td align="left"><bold>13f</bold></td><td align="left">NH</td><td align="left">7-OCH<sub>3</sub></td><td align="char" char=".">0.210&#x02009;&#x000b1;&#x02009;0.098</td><td align="left">0.092&#x02009;&#x000b1;&#x02009;0.0062</td><td align="left">0.187&#x02009;&#x000b1;&#x02009;0.009</td><td align="left">0.101&#x02009;&#x000b1;&#x02009;0.090</td></tr><tr><td align="left"><bold>13g</bold></td><td align="left">NH</td><td align="left">7-OCH(CH<sub>3</sub>)<sub>2</sub></td><td align="char" char=".">5.114&#x02009;&#x000b1;&#x02009;0.410</td><td align="left">5.562&#x02009;&#x000b1;&#x02009;0.133</td><td align="left">1.620&#x02009;&#x000b1;&#x02009;0.950</td><td align="left">4.439&#x02009;&#x000b1;&#x02009;0.600</td></tr><tr><td align="left"><bold>13h</bold></td><td align="left">NH</td><td align="left">7-OCH<sub>2</sub>Ph</td><td align="char" char=".">4.931&#x02009;&#x000b1;&#x02009;0.260</td><td align="left">1.695&#x02009;&#x000b1;&#x02009;0.821</td><td align="left">2.610&#x02009;&#x000b1;&#x02009;0.430</td><td align="left">2.070&#x02009;&#x000b1;&#x02009;0.390</td></tr><tr><td align="left"><bold>CA-4</bold></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="char" char=".">0.076&#x02009;&#x000b1;&#x02009;0.004</td><td align="left">0.019&#x02009;&#x000b1;&#x02009;0.004</td><td align="left">0.026&#x02009;&#x000b1;&#x02009;0.001</td><td align="left">0.064&#x02009;&#x000b1;&#x02009;0.004</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p><sup>a</sup>IC<sub>50</sub> values are half maximal inhibitory concentrations required to block the growth stimulation of cells. Values represent the mean for three experiments performed in triplicate.</p></fn></table-wrap-foot></table-wrap></sec><sec id="S0003-S2002" disp-level="2"><label>3.2.</label><title>Biological results and discussion</title><sec id="S0003-S2002-S3001" disp-level="3"><label>3.2.1.</label><title><italic>In vitro</italic> antiproliferative activities</title><p>All the synthesised compounds (with CA-4 as a positive reference) were evaluated for their antiproliferative activities using MTT assay with four different cancer cell lines &#x02013; MCF-7 breast adenocarcinoma, HL-60 leukaemia, HCT-116 colorectal carcinoma, and HeLa cervical adenocarcinoma. As shown in <xref rid="t0001" ref-type="table">Table 1</xref>, most of the compounds demonstrated moderate to highly potent antiproliferative activities. In the oxazolone analogues (<bold>12a</bold>&#x02013;<bold>h</bold>), compound <bold>12a</bold> without any substituent on the quinoline ring was the least active when compared with quinoline ring substituted compounds. The relative position of the substituent on the quinoline ring also seemed to be critical for antiproliferative activity. Compound <bold>12c</bold> with methyl group at the 7-position ring displayed impressive non-selective potency in nanomolar range against HL-60, MCF-7, HCT-116 and HeLa cell lines with IC<sub>50</sub> of 0.019, 0.010, 0.022 and 0.042&#x02009;&#x000b5;M, which compared to 0.076, 0.019. 0.026 and 0.064&#x02009;&#x000b5;M for CA-4, respectively. In contrast, both the 6-CH<sub>3</sub> analog (<bold>12b</bold>) and 8-CH<sub>3</sub> analog (<bold>12d</bold>) were 3- to 15-fold less active than <bold>12c</bold>. The nature of the substituents on the quinoline ring of the oxazolone compounds was also found to significantly influence the biological activity. For example, replacement of the methyl group in <bold>12b</bold> and <bold>12c</bold> with a stronger electron-releasing methoxy group yielded compounds <bold>12e</bold> and <bold>12f</bold>, respectively, which resulted in better antiproliferative activities. The methoxy-containing compound <bold>12e</bold> was 2.7- to 13-fold more active than the methyl-containing compound <bold>12b</bold> with the four cancer cell lines (IC<sub>50</sub> of 0.068, 0.056, 0.031 and 0.010&#x02009;&#x000b5;M in HL-60, MCF-7, HCT-116 and HeLa cancer cell lines, respectively). Compound <bold>12f</bold> had a similar effect as <bold>12c</bold> against MCF-7 and HCT-116 cells (0.052 and 0.066&#x02009;&#x000b5;M, respectively), but with reduction in activity against the other two cell lines, HL-60 and HeLa (0.352 and 0.138&#x02009;&#x000b5;M, respectively). Introducing larger substituents at the quinoline ring as in <bold>12g</bold> (7-<italic>tert</italic>-butyl) and <bold>12h</bold> (7-benzyloxy) led to a dramatic decrease in activity compared to their corresponding analog <bold>12f</bold> (7-methoxy). Summarily, adding smaller and/or polar groups to the quinoline ring of the oxazolone resulted in significant improvement in the antiproliferative activity.</p><p>The imidazolones (Compound <bold>13a</bold>&#x02013;<bold>h)</bold> also resulted in impressive antiproliferative activity with IC<sub>50</sub> values ranging from 0.04&#x02013;8.21&#x02009;&#x000b5;M in all four cell lines. In general, the imidazolones showed similar antiproliferative activities as the oxazolones (<xref rid="t0001" ref-type="table">Table 1</xref>), which could be due to similar electronic effects of the oxazolone and imidazolone rings. Like the oxazolone, lack of substituent on the quinolone ring as in compound <bold>13a</bold> led to reduction in activity, with IC<sub>50</sub> values of more than 1&#x02009;&#x000b5;M in all four cell lines, similar to the results obtained with the oxazolone derivative <bold>12a</bold>. Methyl substitution on the quinoline ring, e.g. 6-CH<sub>3</sub>
<bold>13b</bold>, 7-CH<sub>3</sub>
<bold>13c</bold> and 8-CH<sub>3</sub>
<bold>13d</bold> led to potent activity in submicromolar range in all four cancer cell lines.</p><p>The position of the methoxy substituent on the quinoline heterocycle also influenced the antiproliferative activity of the compounds against the cancer cell lines. For example, the antiproliferative activity of 6-methoxy-substituted <bold>13e</bold> was better than its analog 7-methoxy-substituted <bold>13f</bold> against MCF-7, HCT-116 and HeLa cells with IC<sub>50</sub> values of 0.042, 0.085 and 0.062&#x02009;&#x000b5;M, which compare to 0.092, 0.187 and 0.101&#x02009;&#x000b5;M for <bold>13f</bold>, respectively. However, in HL-60, <bold>13e</bold> exhibited less antiproliferative activity with IC<sub>50</sub> value of 0.272&#x02009;&#x000b5;M. In a similar trend as the oxazolone derivatives, bulky substituents on the quinoline ring <bold>13g</bold> (7-<italic>tert</italic>-butyl) and <bold>13h</bold> (7-benzyloxy) resulted in drastic decrease in activity in all four cancer cell lines with 14- to 125-fold loss in potency compared to their corresponding <bold>13f</bold> (7-methoxy containing) compound.</p><p>In summary, both oxazolone and imidazolone compounds displayed potent antiproliferative effects, strengthening our hypothesis that nitrogen-containing heterocycles, such as quinoline, are beneficial surrogates for the ring B of CA-4. The different biological activities of the compounds are likely the result of differences in their mode of interaction with the colchicine binding site. Due to its excellent antiproliferative activity, compound <bold>12c</bold> was studied in more details as described below.</p></sec><sec id="S0003-S2002-S3002" disp-level="3"><label>3.2.2.</label><title><italic>In vitro</italic> inhibition of tubulin polymerisation and colchicine binding</title><p>Trimethoxyphenyl (TMP) containing stilbenoid derived compounds, such as colchicine, resveratrol and CA-4 bind to tubulin at the colchicine binding site, resulting in inhibition of microtubule polymerisation<xref rid="CIT0059" ref-type="bibr"><sup>59</sup></xref><sup>,</sup><xref rid="CIT0060" ref-type="bibr"><sup>60</sup></xref>. To confirm whether the quinoline compounds similarly target the tubulin-microtubule system, representative quinoline compounds, including four oxazolone analogues (<bold>12a</bold>, <bold>12c</bold>, <bold>12e</bold> and <bold>12g</bold>) and two imidazolone analogues (<bold>13c</bold> and <bold>13e</bold>), as well as the reference compound CA-4, were evaluated for their antitubulin polymerisation activities and the results presented in <xref rid="t0002" ref-type="table">Table 2</xref>. The methyl and methoxy substituted oxazolone compounds <bold>12c</bold> and <bold>12e,</bold> respectively strongly inhibited tubulin assembly with IC<sub>50</sub> of 1.21 and 2.26&#x02009;&#x000b5;M, respectively compared to that of CA-4 (IC<sub>50</sub> of 2.17&#x02009;&#x000b5;M), while the unsubstituted analogue <bold>12a</bold> (IC<sub>50</sub> of 13.98&#x02009;&#x000b5;M) and <italic>tert-</italic>butyl analog <bold>12g</bold> (IC<sub>50</sub> of 8.23&#x02009;&#x000b5;M) were 6- and 4-fold less active than CA-4. The imidazolone compound <bold>13e</bold> with IC<sub>50</sub> of 1.48&#x02009;&#x000b5;M also showed very potent tubulin polymerisation inhibition compared to CA-4. The methyl analogue <bold>13c</bold> was inactive in the tubulin polymerisation assay (IC<sub>50</sub> of 20.29&#x02009;&#x000b5;M), and is 16-fold less active compared to its corresponding oxazolone derivative <bold>12c</bold>, which is in agreements with the poor cell growth inhibitory activity of <bold>13c</bold> compared to <bold>12c</bold>.</p><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Inhibition of Tubulin Polymerisation and Colchicine Binding by quinoline compounds and CA-4.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th rowspan="3" align="left">Compound number</th><th align="center">Tubulin assembly<sup>a</sup><hr/></th><th colspan="2" align="center">Colchicine binding<sup>b</sup><hr/></th></tr><tr><th rowspan="2" align="center">IC<sub>50</sub> (&#x000b5;M)</th><th colspan="2" align="center">%&#x000b1; SD<hr/></th></tr><tr><th align="center">1 &#x000b5;M drug</th><th align="center">5 &#x000b5;M drug</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>12a</bold></td><td align="char" char=".">13.98</td><td align="center">nd</td><td align="center">nd</td></tr><tr><td align="left"><bold>12c</bold></td><td align="char" char=".">1.21</td><td align="center">79&#x02009;&#x000b1;&#x02009;2</td><td align="center">87&#x02009;&#x000b1;&#x02009;1</td></tr><tr><td align="left"><bold>12e</bold></td><td align="char" char=".">2.26</td><td align="center">nd</td><td align="center">nd</td></tr><tr><td align="left"><bold>12g</bold></td><td align="char" char=".">8.23</td><td align="center">nd</td><td align="center">nd</td></tr><tr><td align="left"><bold>13c</bold></td><td align="char" char=".">20.29</td><td align="center">nd</td><td align="center">nd</td></tr><tr><td align="left"><bold>13e</bold></td><td align="char" char=".">1.48</td><td align="center">nd</td><td align="center">nd</td></tr><tr><td align="left"><bold>CA-4</bold></td><td align="char" char=".">2.17</td><td align="center">86&#x02009;&#x000b1;&#x02009;0.9</td><td align="center">97&#x02009;&#x000b1;&#x02009;2</td></tr></tbody></table><table-wrap-foot><fn id="TF2"><p><sup>a</sup>Inhibition of tubulin polymerisation. Tubulin was at 10&#x02009;&#x000b5;M.</p></fn><fn id="TF3"><p><sup>b</sup>Inhibition of [<sup>3</sup>H] colchicine binding. Tubulin and colchicine were at 1 and 5&#x02009;&#x000b5;M concentrations, respectively.</p></fn></table-wrap-foot></table-wrap><p>Compound <bold>12c</bold> was also examined at two different concentrations (1 and 5&#x02009;&#x000b5;M) for its ability to compete with colchicine for binding to tubulin using a [<sup>3</sup>H] colchicine binding assay. Compound <bold>12c</bold> strongly inhibited colchicine binding to tubulin by 79% and 87% at 1 and 5&#x02009;&#x000b5;M respectively, which compares with 86% and 97% inhibition by CA-4, respectively. These results suggest that compound <bold>12c</bold> is involved in tubulin polymerisation inhibition through the colchicine-binding site.</p></sec><sec id="S0003-S2002-S3003" disp-level="3"><label>3.2.3.</label><title>Cell cycle analysis</title><p>Induction of cell cycle arrest at G<sub>2</sub>/M phase is strongly accompanied with tubulin polymerisation inhibition. It is well established that CA-4 arrests cell cycle at G<sub>2</sub>M phase<xref rid="CIT0061" ref-type="bibr"><sup>61&#x02013;63</sup></xref>. To further gain insight into compound <bold>12c</bold> potent antiproliferative activity, cell cycle analysis of MCF-7 cells was performed at two concentrations of 50&#x02009;nM and 250&#x02009;nM and at different time points of 0, 24, 48 and 72&#x02009;h. <xref ref-type="fig" rid="F0003">Figure 3(A)</xref> clearly demonstrates that <bold>12c</bold> caused a significant arrest in G<sub>2</sub>/M phase and apoptosis in a dose- and time-dependent manner. After 48&#x02009;h, the percentage of G<sub>2</sub>/M phase arrested cells were 28.4% and 38.3% at 50&#x02009;nM and 250&#x02009;nM, respectively compared to 9.2% of untreated cells (<xref ref-type="fig" rid="F0003">Figure 3(B)</xref>). Moreover, there was an increase in the number of cells in G<sub>2</sub>/M phase after 72&#x02009;h (33.0% and 40.8% at 50&#x02009;nM and 250&#x02009;nM, respectively) with a concomitant decrease of cells in G<sub>0</sub>/G<sub>1</sub> phase (40.3% and 29.8% at 50&#x02009;nM and 250&#x02009;nM, respectively) compared to the control (57.3%). In a comparable finding, CA-4 (50&#x02009;nM) also significantly arrested G<sub>2</sub>/M phase at 24, 48 and 72&#x02009;h (40.3%, 43.8% and 47.7%, respectively). Accordingly, a concomitant decrease of MCF-7 cells was detected in G0 phase (<xref ref-type="fig" rid="F0003">Figure 3(C)</xref>). Furthermore, compound <bold>12c</bold> induced a gradual increase in apoptosis (16.2%, 23.4% and 32.7%) at 250&#x02009;nM as the proportion of cells in the sub-G1 phase increased at 24, 48 and 72&#x02009;h, respectively compared to untreated cells (1.5%) (<xref ref-type="fig" rid="F0003">Figure 3(D)</xref>). Similarly, 23.5%, 31.1% and 37.4% increase in apoptosis was observed for CA-4 at 24, 48 and 72&#x02009;h, respectively. These findings are in agreement with previously reported for a series of related quinoline analogues, which significantly induced apoptosis and G<sub>2</sub>/M cycle arrest in MCF-7 cells<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="CIT0042" ref-type="bibr"><sup>42</sup></xref><sup>,</sup><xref rid="CIT0046" ref-type="bibr"><sup>46</sup></xref><sup>,</sup><xref rid="CIT0064" ref-type="bibr"><sup>64</sup></xref>.</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>(A) Effect of compound <bold>12c</bold> on the cell cycle and apoptosis in MCF-7 cells. Cells were treated with either vehicle [0.1% ethanol (v/v)], CA-4 (50&#x02009;nM), <bold>12c</bold> (50&#x02009;nM and 250&#x02009;nM) for 24&#x02009;h, 48&#x02009;h and 72&#x02009;h. Cells were then fixed, stained with PI, and analysed by flow cytometry. Cell cycle analysis was performed on histograms of gated counts per DNA area (FL2-A). The number of cells with (B) 4&#x02009;N (G<sub>2</sub>/M), (C) 2&#x02009;N(G<sub>0</sub>G<sub>1</sub>), and (D) &#x0003c;2&#x02009;N (sub-G<sub>1</sub>) DNA content was determined with CellQuest software. Values represent the mean&#x02009;&#x000b1;&#x02009;SEM for three independent experiments. Statistical analysis was performed using two-way ANOVA (*<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01; ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001).</p></caption><graphic content-type="color" xlink:href="IENZ_A_1899168_F0003_C"/></fig></sec><sec id="S0003-S2002-S3004" disp-level="3"><label>3.2.4.</label><title>Cell apoptosis</title><p>We investigated whether cell death induced by compound <bold>12c</bold> treatment was related to apoptosis using the Annexin-V/PI double staining flow cytometric assay (<xref ref-type="fig" rid="F0004">Figure 4(A,B)</xref>). MCF-7 cells were treated with three different concentrations (0, 50 and 250&#x02009;nM) of compound <bold>12c</bold> at different time points (24, 48 and 72&#x02009;h). Compound <bold>12c</bold> caused a significant accumulation of annexine-V positive cells and induced both early and late apoptosis in a dose- and time-dependent manner compared to the untreated cells. As shown in <xref ref-type="fig" rid="F0004">Figure 4(B)</xref>, when the cells were treated with <bold>12c (</bold>0 and 250&#x02009;nM) or CA-4 (50&#x02009;nM) for 48&#x02009;h, the percentage of Annexin V-staining positive cells significantly increased from 1% in untreated cells to 15%, 21% and 29% respectively. The percentage of early and late apoptotic cells in the presence of <bold>12c</bold> increased after 72&#x02009;h to 17.6% and 29.3% at 1 and 5&#x02009;&#x000b5;M respectively when compared to the untreated cells (2%). Based on the cell cycle arrest and apoptosis findings (<xref ref-type="fig" rid="F0003">Figure 3(B&#x02013;D)</xref>), it appears that compound <bold>12c</bold> could efficiently induce apoptosis cell death in MCF-7 cells in a dose- and time-dependent manner.</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>(A) Effect of compound <bold>12c</bold> at different time points on apoptosis in MCF-7 cells analysed by flow cytometry after double staining of the cells with Annexin-V-FITC and PI. MCF-7 cells treated with 50 and 250&#x02009;nM of compound <bold>12c</bold> and 50&#x02009;nM of CA-4 for 24&#x02009;h, 48&#x02009;h and 72&#x02009;h and collected and processed for analysis. (B) Quantitative analysis of apoptosis. Values represent the mean&#x02009;&#x000b1;&#x02009;SEM for three independent experiments. Statistical analysis was performed using two-way ANOVA (*<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05** and <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01; ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001).</p></caption><graphic content-type="color" xlink:href="IENZ_A_1899168_F0004_C"/></fig></sec><sec id="S0003-S2002-S3005" disp-level="3"><label>3.2.5.</label><title>Assessment of toxicity to non-tumorigenic human cells</title><p>To assess the cytotoxicity and selectivity of <bold>12c</bold> towards cancer cells, normal epithelial breast MCF-10A cell viability study was carried out. As shown in <xref ref-type="fig" rid="F0005">Figure 5(A)</xref>, the IC<sub>50</sub> value of <bold>12c</bold> was more than 50&#x02009;&#x000b5;M in MCF-10A cells, which was significantly higher than the IC<sub>50</sub> values of 19, 10, 22 and 42&#x02009;nM in MCF-7, HL-60, HCT-116 and HeLa cancer cell lines, respectively. Remarkably, <bold>12c</bold> was found to be less toxic in normal MCF-10A (IC<sub>50</sub> &#x0003e;50&#x02009;&#x000b5;M) when compared to CA-4 (IC<sub>50</sub> = 6.1&#x02009;&#x000b5;M) (<xref ref-type="fig" rid="F0005">Figure 5(B)</xref>), suggesting <bold>12c</bold> to have better selective toxicity against cancer cells.</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Dose response curve for (A) Compound <bold>12c</bold> and (B) CA-4 on the proliferation of breast cancer MCF-7 and normal breast MCF-10A cells. Cells were grown in 96-well plates and treated with serial concentrations of compound <bold>12c or</bold> CA-4 for 72&#x02009;h. Cell viability was expressed as percentage of vehicle control [ethanol 1% (v/v)] treated cells and was measured by MTT assay (average of three independent experiments).</p></caption><graphic content-type="color" xlink:href="IENZ_A_1899168_F0005_C"/></fig></sec><sec id="S0003-S2002-S3006" disp-level="3"><label>3.2.6.</label><title>Expression of the apoptotic proteins in MCF-7 cell lines</title><p>The previous data clearly demonstrate that <bold>12c</bold> is an effective anti-mitotic quinoline compound in MCF-7 cell lines. Herein, the effect of <bold>12c</bold> on the expression of apoptosis pathway markers, Bcl-2 anti-apoptotic protein and Bax pro-apoptotic protein was investigated. MCF-7 cells treated with <bold>12c</bold> at 250&#x02009;nM for 48&#x02009;h decreased the expression level of the anti-apoptotic protein Bcl-2, and correspondingly up-regulated the expression of the pro-apoptotic protein Bax (<xref ref-type="fig" rid="F0006">Figure 6(A,B)</xref>).</p><fig id="F0006" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>Effect of compound <bold>12c</bold> on the expression (A) anti-apoptotic protein Bcl2, (B) pro-apoptotic protein BAX and (C) Caspase 9 in MCF-7 cells.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1899168_F0006_C"/></fig><p>Activation of caspases initiates apoptosis, and in particular caspase-9 is considered an important effector caspase responsible for programmed cell death apoptosis activated by CA-4<xref rid="CIT0061" ref-type="bibr"><sup>61</sup></xref><sup>,</sup><xref rid="CIT0065" ref-type="bibr"><sup>65</sup></xref><sup>,</sup><xref rid="CIT0066" ref-type="bibr"><sup>66</sup></xref>. The amount of activated caspase-9 was examined in MCF-7 cells treated with <bold>12c</bold>. As observed from <xref ref-type="fig" rid="F0006">Figure 6(C)</xref>, compound <bold>12c</bold> at 50 and 250&#x02009;nM produced about 8- and 16-fold increases in caspase-9 activation respectively when compared to 14-fold for CA-4 (50&#x02009;nM). This finding confirms that compound <bold>12c</bold> like CA-4 enhanced the rate of apoptosis in MCF-7 cell through caspase-9 activation.</p></sec><sec id="S0003-S2002-S3007" disp-level="3"><label>3.2.7.</label><title>Inhibition of colony formation</title><p>Colony formation assay is one of the effective techniques for the determination of long-term cell proliferation upon anticancer drug exposure. The inhibitory potential of <bold>12c</bold> on MCF-7 cells colony formation is displayed in <xref ref-type="fig" rid="F0007">Figure 7</xref>. Compound <bold>12c</bold> suppressed the clonogenic formation potential of MCF-7 cells in a dose dependent manner when compared to CA-4.</p><fig id="F0007" orientation="portrait" position="float"><label>Figure 7.</label><caption><p>(A) Inhibition of colony formation in MCF-7 cells by 50 and 250&#x02009;nM of compound <bold>12c</bold> and 50&#x02009;nM of CA-4 for 48&#x02009;h. (B) Quantitative analysis of colony formation. .</p></caption><graphic content-type="color" xlink:href="IENZ_A_1899168_F0007_C"/></fig></sec><sec id="S0003-S2002-S3008" disp-level="3"><label>3.2.8.</label><title>Wound healing assay</title><p>Migration and motility of cancer cells are considered as critical factors in tumour progression and metastasis<xref rid="CIT0067" ref-type="bibr"><sup>67</sup></xref><sup>,</sup><xref rid="CIT0068" ref-type="bibr"><sup>68</sup></xref>. In order to investigate the effect of compound <bold>12c</bold> on the migration of MCF-7, wound healing assay was performed. As illustrated in <xref ref-type="fig" rid="F0008">Figure 8(A,B)</xref>, the untreated cells migrated to the scraped area while in <bold>12c</bold>-treated wells, cell migration was significantly inhibited in a dose-dependent manner. This significant difference in the wound area confirms that <bold>12c</bold> suppressed MCF-7 cell migration, an important event in tumour metastasis.</p><fig id="F0008" orientation="portrait" position="float"><label>Figure 8.</label><caption><p>(A) Inhibition of the migration of MCF-7 cells treated with compound <bold>12c</bold> for 48&#x02009;h in the wound healing assay. (B) Quantitative analysis of wound closure rate and was calculated as mean&#x02009;&#x000b1;&#x02009;SEM for three independent experiments. Statistical analysis was performed using one-way ANOVA-Bonferroni post-hoc test (***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001).</p></caption><graphic content-type="color" xlink:href="IENZ_A_1899168_F0008_C"/></fig></sec><sec id="S0003-S2002-S3009" disp-level="3"><label>3.2.9.</label><title>Mitochondrial membrane potential</title><p>Mitochondria membrane potential plays a crucial role in the propagation of apoptosis. Specifically, loss of mitochondrial membrane potential &#x00394;&#x003c8;<sub>mt</sub> (MMP) is characteristic of early stage of apoptosis<xref rid="CIT0069" ref-type="bibr"><sup>69&#x02013;71</sup></xref>. To confirm whether compound <bold>12c</bold> could decrease the MMP of MCF-7 cancer cells, MMP was monitored by the fluorescence of the dye DiOC2(3). MCF-7 cells treated with <bold>12c</bold> at 50 and 250&#x02009;nM exhibited significant decrease in MMP in a dose- and time-dependant manner (<xref ref-type="fig" rid="F0009">Figure 9(A)</xref>). This depletion in MMP was associated with an increase of annexin-V positive early apoptotic cells. Maximum decrease in MCF-7 MMP was detected after 24&#x02009;h treatment with <bold>12c</bold> in which the percentage of apoptotic cells increased from 1.1% to 24.9% and 31.3% at 50 and 250&#x02009;nM, respectively (<xref ref-type="fig" rid="F0009">Figure 9(B)</xref>). This indicates that compound <bold>12c</bold> induces mitochondrial dysfunction in MCF-7, which eventually triggered apoptotic cell death. These results are in agreement with previously reported CA-4 analogues study that were shown to cause apoptosis through the mitochondrial pathway<xref rid="CIT0068" ref-type="bibr"><sup>68</sup></xref><sup>,</sup><xref rid="CIT0072" ref-type="bibr"><sup>72</sup></xref><sup>,</sup><xref rid="CIT0073" ref-type="bibr"><sup>73</sup></xref>.</p><fig id="F0009" orientation="portrait" position="float"><label>Figure 9.</label><caption><p>Assessment of mitochondrial membrane potential (&#x00394;&#x003c8;<sub>mt</sub>) after treatment of MCF-7 cells with <bold>12c</bold>. Cells were treated with indicated concentration of compound <bold>12c</bold> for 6, 12 and 24&#x02009;h and then stained with fluorescent DiOC2(3) for analysis of mitochondrial potential. Cells were then analysed by flow cytometry as described in the experimental section. Data are presented as mean&#x02009;&#x000b1;&#x02009;SEM of three independent experiments. Statistical analysis was performed using two-way ANOVA (**<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01; ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001).</p></caption><graphic content-type="color" xlink:href="IENZ_A_1899168_F0009_C"/></fig></sec><sec id="S0003-S2002-S3010" disp-level="3"><label>3.2.10.</label><title>Intracellular reactive oxygen species (ROS) production</title><p>The dissipation of mitochondrial potential is strongly associated with mitochondrial production of reactive oxygen species (ROS)<xref rid="CIT0071" ref-type="bibr"><sup>71</sup></xref><sup>,</sup><xref rid="CIT0073" ref-type="bibr"><sup>73</sup></xref>. The production of ROS after <bold>12c</bold> treatment at 50 and 250&#x02009;nM, as well as CA-4 (50&#x02009;nM) with hydrogen peroxide H<sub>2</sub>O<sub>2</sub> was followed with 2,7&#x02013;dichlorofluorescin diacetate (H<sub>2</sub>-DCFDA). As shown in <xref ref-type="fig" rid="F0010">Figure 10</xref>, after 24&#x02009;h of <bold>12c</bold> treatment, the levels of ROS in MCF-7 cells were 22.7 and 26.6% at 50 and 250&#x02009;nM, respectively. The level in untreated MCF-7 cells was 1.0%, while it increased only to 18.3% in CA-4-treated cells. This result along with the significant loss of mitochondrial membrane potential above clearly suggests that compound <bold>12c</bold> induced apoptosis via the mitochondrial pathway.</p><fig id="F0010" orientation="portrait" position="float"><label>Figure 10.</label><caption><p>Effect of compound <bold>12c</bold> at different time points on ROS production in MCF-7 cells. MCF-7 cells treated without and with 50 and 250&#x02009;nM of compound <bold>12c</bold> and 50&#x02009;nM of CA-4 and 100&#x02009;&#x000b5;M H<sub>2</sub>O<sub>2</sub> for 6&#x02009;h, 12&#x02009;h and 24&#x02009;h. Cells were incubated with DCFDA (25&#x02009;&#x000b5;M) dye for 1&#x02009;h at 37&#x02009;&#x000b0;C in dark. Fluorescence intensity per cell at 525&#x02009;nm was calculated as mean&#x02009;&#x000b1;&#x02009;SEM for three independent experiments. Statistical analysis was performed using two-way ANOVA (***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001).</p></caption><graphic content-type="color" xlink:href="IENZ_A_1899168_F0010_C"/></fig></sec></sec></sec><sec sec-type="conclusions" id="S0004" disp-level="1"><label>4.</label><title>Conclusion</title><p>In this study, we designed, synthesised and evaluated two classes of novel quinoline compounds combretastatin A-4 derivatives as potential inhibitors of tubulin polymerisation. Several other studies have also reported derivatisation of the CA-4 pharmacophore with varying success<xref rid="CIT0027" ref-type="bibr"><sup>27&#x02013;32</sup></xref>. Unlike the previous compounds, we for the first time introduced a chalcone system, including oxazolones and imidazolones to the <italic>cis</italic> bond of CA-4 to give more rigidity to the required active conformation. The chalcone system is well known for its anticancer activities. Our design also kept the essential natural trimethoxyphenyl pharmacophore (found in CA-4), while varying the electronic substituents effect on the quinolyl moiety (ring B) that were expected to enhance the potency of the compounds. Most of the compounds showed significant and, in some instances, comparable antiproliferative activities against different cancer cell lines as the previously studied combretastatin A-4 compound, CA-4. One of the most promising compound <bold>12c</bold> showed potent anti-proliferative activities against HL-60, MCF-7, HCT-116 and HeLA cancer cell lines with IC<sub>50</sub> values of 0.019, 0.010, 0.022 and 0.042&#x02009;&#x000b5;M, respectively, and simultaneously low cytotoxicity towards MCF-10A non-cancer cells. The microtubule polymerisation inhibitory effect of <bold>12c</bold> was confirmed with an <italic>in&#x000a0;vitro</italic> tubulin polymerisation and colchicine inhibition assays. Compound <bold>12c</bold> effectively block the G<sub>2</sub>/M phase at the cell cycle and induce MCF-7 cell apoptosis together with significant change of Bax/Bcl expression ratio indicating involvement of mitochondrial apoptosis pathway. Further cellular mechanistic studies confirmed that <bold>12c</bold> inhibited MCF-7 cell migration and colony formation. In conclusion, these results highlight our novel quinoline compounds and particularly <bold>12c</bold> as promising anti-tubulin agent for the treatment of MCF-7 breast cancer cells. Moreover, the results point to a direction for rational development of potent tubulin polymerisation inhibitors for the treatment of cancer.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors gratefully acknowledge DSR technical and financial support.</p></ack><sec id="S0005" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>The authors declare no competing interests.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bray</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Ferlay</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Soerjomataram</surname>
<given-names>I</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source>
<year>2018</year>;<volume>68</volume>:<fpage>394</fpage>&#x02013;<lpage>424</lpage>.<pub-id pub-id-type="pmid">30207593</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Decosterd</surname>
<given-names>LA</given-names></string-name>, <string-name><surname>Widmer</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Zaman</surname>
<given-names>K</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Therapeutic drug monitoring of targeted anticancer therapy</article-title>. <source>Biomark Med</source>
<year>2015</year>;<volume>9</volume>:<fpage>887</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">26333311</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>La Regina</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Coluccia</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Naccarato</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Silvestri</surname>
<given-names>R.</given-names></string-name></person-group>
<article-title>Towards modern anticancer agents that interact with tubulin</article-title>. <source>Eur J Pharm Sci</source>
<year>2019</year>;<volume>131</volume>:<fpage>58</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">30690185</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stec-Martyna</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Ponassi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Miele</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structural comparison of the interaction of tubulin with various ligands affecting microtubule dynamics</article-title>. <source>Curr Cancer Drug Targets</source>
<year>2012</year>;<volume>12</volume>:<fpage>658</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">22385515</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Devi Tangutur</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kumar</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Vamsi Krishna</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Kantevari</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>Microtubule targeting agents as cancer chemotherapeutics: An overview of molecular hybrids as stabilizing and destabilizing agents</article-title>. <source>Curr Top Med Chem</source>
<year>2017</year>;<volume>17</volume>:<fpage>2523</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="pmid">28056738</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kavallaris</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>Microtubules and resistance to tubulin-binding agents</article-title>. <source>Nat Rev Cancer</source>
<year>2010</year>;<volume>10</volume>:<fpage>194</fpage>&#x02013;<lpage>204</lpage>.<pub-id pub-id-type="pmid">20147901</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Coulup</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Georg</surname>
<given-names>GI.</given-names></string-name></person-group>
<article-title>Revisiting microtubule targeting agents: &#x00391;-tubulin and the pironetin binding site as unexplored targets for cancer therapeutics</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2019</year>;<volume>29</volume>:<fpage>1865</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">31130264</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vindya</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Sharma</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Yadav</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ethiraj</surname>
<given-names>K.</given-names></string-name></person-group>
<article-title>Tubulins &#x02013; the target for anticancer therapy</article-title>. <source>Curr Top Med Chem</source>
<year>2015</year>;<volume>15</volume>:<fpage>73</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">25579568</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dumontet</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Jordan</surname>
<given-names>MA.</given-names></string-name></person-group>
<article-title>Microtubule-binding agents: a dynamic field of cancer therapeutics</article-title>. <source>Nat Rev Drug Discov</source>
<year>2010</year>;<volume>9</volume>:<fpage>790</fpage>&#x02013;<lpage>803</lpage>.<pub-id pub-id-type="pmid">20885410</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sharma</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kaur</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Budhiraja</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Chalcone based azacarboline analogues as novel antitubulin agents: design, synthesis, biological evaluation and molecular modelling studies</article-title>. <source>Eur J Med Chem</source>
<year>2014</year>;<volume>85</volume>:<fpage>648</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">25128667</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kaur</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Kaur</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Gill</surname>
<given-names>RK</given-names></string-name>, <string-name><surname>Soni</surname>
<given-names>R</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Recent developments in tubulin polymerization inhibitors: an overview</article-title>. <source>Eur J Med Chem</source>
<year>2014</year>;<volume>87</volume>:<fpage>89</fpage>&#x02013;<lpage>124</lpage>.<pub-id pub-id-type="pmid">25240869</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bukhari</surname>
<given-names>SNA</given-names></string-name>, <string-name><surname>Kumar</surname>
<given-names>GB</given-names></string-name>, <string-name><surname>Revankar</surname>
<given-names>HM</given-names></string-name>, <string-name><surname>Qin</surname>
<given-names>HL.</given-names></string-name></person-group>
<article-title>Development of combretastatins as potent tubulin polymerization inhibitors</article-title>. <source>Bioorg Chem</source>
<year>2017</year>;<volume>72</volume>:<fpage>130</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">28460355</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Naumova</surname>
<given-names>N</given-names></string-name>, <string-name><surname>&#x00160;achl</surname>
<given-names>R.</given-names></string-name></person-group>
<article-title>Regulation of cell death by mitochondrial transport systems of calcium and bcl-2 proteins</article-title>. <source>Membranes</source>
<year>2020</year>;<volume>10</volume>:<fpage>299</fpage>.</mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thomas</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Gopalakrishnan</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Hegde</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A novel resveratrol based tubulin inhibitor induces mitotic arrest and activates apoptosis in cancer cells</article-title>. <source>Sci Rep</source>
<year>2016</year>;<volume>6</volume>:<fpage>34653</fpage>.<pub-id pub-id-type="pmid">27748367</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Naaz</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Haider</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>Shafi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Yar</surname>
<given-names>MS.</given-names></string-name></person-group>
<article-title>Anti-tubulin agents of natural origin: targeting taxol, vinca, and colchicine binding domains</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>;<volume>171</volume>:<fpage>310</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">30953881</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cao</surname>
<given-names>YN</given-names></string-name>, <string-name><surname>Zheng</surname>
<given-names>LL</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>D</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Recent advances in microtubule-stabilizing agents</article-title>. <source>Eur J Med Chem</source>
<year>2018</year>;<volume>143</volume>:<fpage>806</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">29223097</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Cragg</surname>
<given-names>GM</given-names></string-name>, <string-name><surname>Kingston</surname>
<given-names>DG</given-names></string-name>, <string-name><surname>Newman</surname>
<given-names>DJ.</given-names></string-name></person-group>
<source>Anticancer agents from natural products</source>. <publisher-loc>Boca Raton (FL)</publisher-loc>: <publisher-name>CRC press</publisher-name>; <year>2012</year>.</mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gupta</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Singh</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Ali</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Verma</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>Role of membrane-embedded drug efflux abc transporters in the cancer chemotherapy</article-title>. <source>Oncol Rev</source>
<year>2020</year>;<volume>14</volume>:<fpage>448</fpage>.<pub-id pub-id-type="pmid">32676170</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arnst</surname>
<given-names>KE</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Lei</surname>
<given-names>ZN</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Colchicine binding site agent dj95 overcomes drug resistance and exhibits antitumor efficacy</article-title>. <source>Mol Pharmacol</source>
<year>2019</year>;<volume>96</volume>:<fpage>73</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="pmid">31043459</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zweifel</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Jayson</surname>
<given-names>GC</given-names></string-name>, <string-name><surname>Reed</surname>
<given-names>N</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Phase ii trial of combretastatin a4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer</article-title>. <source>Ann Oncol</source>
<year>2011</year>;<volume>22</volume>:<fpage>2036</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">21273348</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Sun</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures</article-title>. <source>Future Med Chem</source>
<year>2017</year>;<volume>9</volume>:<fpage>1765</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">28929799</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kamath</surname>
<given-names>PR</given-names></string-name>, <string-name><surname>Sunil</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Ajees</surname>
<given-names>AA.</given-names></string-name></person-group>
<article-title>Synthesis of indole&#x02013;quinoline&#x02013;oxadiazoles: their anticancer potential and computational tubulin binding studies</article-title>. <source>Res Chem Intermed</source>
<year>2016</year>;<volume>42</volume>:<fpage>5899</fpage>&#x02013;<lpage>914</lpage>.</mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khelifi</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Naret</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Renko</surname>
<given-names>D</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis and anticancer properties of isocombretaquinolines as potent tubulin assembly inhibitors</article-title>. <source>Eur J Med Chem</source>
<year>2017</year>;<volume>127</volume>:<fpage>1025</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">28166995</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Seligmann</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Twelves</surname>
<given-names>C.</given-names></string-name></person-group>
<article-title>Tubulin: an example of targeted chemotherapy</article-title>. <source>Future Med Chem</source>
<year>2013</year>;<volume>5</volume>:<fpage>339</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">23464522</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pieku&#x0015b;-S&#x00142;omka</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Mikstacka</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Ronowicz</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Sobiak</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>Hybrid cis-stilbene molecules: novel anticancer agents</article-title>. <source>Int J Mol Sci</source>
<year>2019</year>;<volume>20</volume>:<fpage>1300</fpage>.</mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haider</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Rahaman</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Yar</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Kamal</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018)</article-title>. <source>Expert Opin Ther Pat</source>
<year>2019</year>;<volume>29</volume>:<fpage>623</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">31353978</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Das</surname>
<given-names>BC</given-names></string-name>, <string-name><surname>Tang</surname>
<given-names>XY</given-names></string-name>, <string-name><surname>Rogler</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Evans</surname>
<given-names>T.</given-names></string-name></person-group>
<article-title>Design and synthesis of 3,5-disubstituted boron-containing 1,2,4-oxadiazoles as potential combretastatin a-4 (ca-4) analogs</article-title>. <source>Tetrahedron Lett</source>
<year>2012</year>;<volume>53</volume>:<fpage>3947</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">24039307</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Biersack</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Effenberger</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Schobert</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Ocker</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>Oxazole-bridged combretastatin a analogues with improved anticancer properties</article-title>. <source>ChemMedChem</source>
<year>2010</year>;<volume>5</volume>:<fpage>420</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">20112324</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mahal</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Biersack</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Schruefer</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Combretastatin a-4 derived 5-(1-methyl-4-phenyl-imidazol-5-yl)indoles with superior cytotoxic and anti-vascular effects on chemoresistant cancer cells and tumors</article-title>. <source>Eur J Med Chem</source>
<year>2016</year>;<volume>118</volume>:<fpage>9</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">27116710</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Biernacki</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Da&#x0015b;ko</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ciupak</surname>
<given-names>O</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel 1,2,4-oxadiazole derivatives in drug discovery</article-title>. <source>Pharmaceuticals (Basel)</source>
<year>2020</year>;<volume>13</volume>:<fpage>111</fpage>.</mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schmitt</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Gosch</surname>
<given-names>LC</given-names></string-name>, <string-name><surname>Dittmer</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Oxazole-bridged combretastatin A-4 derivatives with tethered hydroxamic acids: structure(-)activity relations of new inhibitors of hdac and/or tubulin function</article-title>. <source>Int J Mol Sci</source>
<year>2019</year>;<volume>20</volume>:<fpage>283</fpage>.</mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Quan</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>J</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis, and biological evaluation of 1-substituted-2-aryl imidazoles targeting tubulin polymerization as potential anticancer agents</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>;<volume>184</volume>:<fpage>111732</fpage>.<pub-id pub-id-type="pmid">31610372</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ibrahim</surname>
<given-names>TS</given-names></string-name>, <string-name><surname>Hawwas</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Malebari</surname>
<given-names>AM</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Potent quinoline-containing combretastatin a-4 analogues: design, synthesis, antiproliferative, and anti-tubulin activity</article-title>. <source>Pharmaceuticals (Basel)</source>
<year>2020</year>;<volume>13</volume>:<fpage>393</fpage>.</mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jian</surname>
<given-names>XE</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>CS</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and biological evaluation of novel pyrazolo[3,4-b]pyridines as cis-restricted combretastatin a-4 analogues</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2020</year>;<volume>30</volume>:<fpage>127025</fpage>.<pub-id pub-id-type="pmid">32063430</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Jian</surname>
<given-names>XE</given-names></string-name>, <string-name><surname>Diao</surname>
<given-names>PC</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis, and biological evaluation of 3,6-diaryl-[1,2,4]triazolo[4,3-a]pyridine analogues as new potent tubulin polymerization inhibitors</article-title>. <source>Eur J Med Chem</source>
<year>2020</year>;<volume>204</volume>:<fpage>112625</fpage>.<pub-id pub-id-type="pmid">32717486</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Huo</surname>
<given-names>X</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Development of triazolothiadiazine derivatives as highly potent tubulin polymerization inhibitors: structure-activity relationship, in&#x000a0;vitro and in&#x000a0;vivo study</article-title>. <source>Eur J Med Chem</source>
<year>2020</year>;<volume>208</volume>:<fpage>112847</fpage>.<pub-id pub-id-type="pmid">33022479</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kaur</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Jain</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Reddy</surname>
<given-names>RP</given-names></string-name>, <string-name><surname>Jain</surname>
<given-names>R.</given-names></string-name></person-group>
<article-title>Quinolines and structurally related heterocycles as antimalarials</article-title>. <source>Eur J Med Chem</source>
<year>2010</year>;<volume>45</volume>:<fpage>3245</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">20466465</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maurya</surname>
<given-names>SS</given-names></string-name>, <string-name><surname>Khan</surname>
<given-names>SI</given-names></string-name>, <string-name><surname>Bahuguna</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis, antimalarial activity, heme binding and docking studies of n-substituted 4-aminoquinoline-pyrimidine molecular hybrids</article-title>. <source>Eur J Med Chem</source>
<year>2017</year>;<volume>129</volume>:<fpage>175</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">28222317</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vaibhav</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Dinesh Kumar</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Rina</surname>
<given-names>D.</given-names></string-name></person-group>
<article-title>Synthetic methods of quinoline derivatives as potent anticancer agents</article-title>. <source>Mini-Rev Med Chem</source>
<year>2017</year>;<volume>17</volume>:<fpage>1557</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">28494729</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Musiol</surname>
<given-names>R.</given-names></string-name></person-group>
<article-title>An overview of quinoline as a privileged scaffold in cancer drug discovery</article-title>. <source>Expert Opin Drug Discov</source>
<year>2017</year>;<volume>12</volume>:<fpage>583</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">28399679</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Solomon</surname>
<given-names>VR</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>H.</given-names></string-name></person-group>
<article-title>Quinoline as a privileged scaffold in cancer drug discovery</article-title>. <source>Curr Med Chem</source>
<year>2011</year>;<volume>18</volume>:<fpage>1488</fpage>&#x02013;<lpage>508</lpage>.<pub-id pub-id-type="pmid">21428893</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Shuai</surname>
<given-names>W</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery of novel quinoline-chalcone derivatives as potent antitumor agents with microtubule polymerization inhibitory activity</article-title>. <source>J Med Chem</source>
<year>2019</year>;<volume>62</volume>:<fpage>993</fpage>&#x02013;<lpage>1013</lpage>.<pub-id pub-id-type="pmid">30525584</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Shen</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>J</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel 4-acrylamido-quinoline derivatives as potent pi3k/mtor dual inhibitors: The design, synthesis, and in&#x000a0;vitro and in&#x000a0;vivo biological evaluation</article-title>. <source>Front Chem</source>
<year>2019</year>;<volume>7</volume>:<fpage>236</fpage>.<pub-id pub-id-type="pmid">31069214</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>W.</given-names></string-name></person-group>
<article-title>Recent advances in heterocyclic tubulin inhibitors targeting the colchicine binding site</article-title>. <source>Anticancer Agents Med Chem</source>
<year>2016</year>;<volume>16</volume>:<fpage>1325</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">26899186</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nainwal</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Alam</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Shaquiquzzaman</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Marella</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Combretastatin-based compounds with therapeutic characteristics: a patent review</article-title>. <source>Expert Opin Ther Pat</source>
<year>2019</year>;<volume>29</volume>:<fpage>703</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">31369715</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chaudhary</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Venghateri</surname>
<given-names>JB</given-names></string-name>, <string-name><surname>Dhaked</surname>
<given-names>HPS</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel combretastatin-2-aminoimidazole analogues as potent tubulin assembly inhibitors: exploration of unique pharmacophoric impact of bridging skeleton and aryl moiety</article-title>. <source>J Med Chem</source>
<year>2016</year>;<volume>59</volume>:<fpage>3439</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">26938120</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jain</surname>
<given-names>KS</given-names></string-name>, <string-name><surname>Kathiravan</surname>
<given-names>MK</given-names></string-name>, <string-name><surname>Bariwal</surname>
<given-names>JB</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel dual use of formamide-pocl3 mixture for the efficient, one-pot synthesis of condensed 2&#x02009;h-pyrimidin-4-amine libraries under microwave irradiation</article-title>. <source>Synth Commun</source>
<year>2013</year>;<volume>43</volume>:<fpage>719</fpage>&#x02013;<lpage>27</lpage>.</mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ibrahim</surname>
<given-names>TS</given-names></string-name>, <string-name><surname>Bokhtia</surname>
<given-names>RM</given-names></string-name>, <string-name><surname>AL-Mahmoudy</surname>
<given-names>AM</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis and biological evaluation of novel 5-((substituted quinolin-3-yl/1-naphthyl) methylene)-3-substituted imidazolidin-2,4-dione as HIV-1 fusion inhibitors</article-title>. <source>Bioorg Chem</source>
<year>2020</year>;<volume>99</volume>:<fpage>103782</fpage><pub-id pub-id-type="pmid">32229348</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kapoor</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Srivastava</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Panda</surname>
<given-names>D.</given-names></string-name></person-group>
<article-title>Indibulin dampens microtubule dynamics and produces synergistic antiproliferative effect with vinblastine in mcf-7 cells: implications in cancer chemotherapy</article-title>. <source>Sci Rep</source>
<year>2018</year>;<volume>8</volume>:<fpage>12363</fpage>.<pub-id pub-id-type="pmid">30120268</pub-id></mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lai</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Ojha</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>MH</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>1-arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>;<volume>162</volume>:<fpage>612</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">30476825</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Du</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ji</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A novel orally active microtubule destabilizing agent s-40 targets the colchicine-binding site and shows potent antitumor activity</article-title>. <source>Cancer Lett</source>
<year>2020</year>;<volume>495</volume>:<fpage>22</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">32931884</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mohamed</surname>
<given-names>KO</given-names></string-name>, <string-name><surname>Zaki</surname>
<given-names>I</given-names></string-name>, <string-name><surname>El-Deen</surname>
<given-names>IM</given-names></string-name>, <string-name><surname>Abdelhameid</surname>
<given-names>MK.</given-names></string-name></person-group>
<article-title>A new class of diamide scaffold: design, synthesis and biological evaluation as potent antimitotic agents, tubulin polymerization inhibition and apoptosis inducing activity studies</article-title>. <source>Bioorg Chem</source>
<year>2019</year>;<volume>84</volume>:<fpage>399</fpage>&#x02013;<lpage>409</lpage>.<pub-id pub-id-type="pmid">30551066</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Yotnda</surname>
<given-names>P.</given-names></string-name></person-group>
<article-title>Production and detection of reactive oxygen species (ros) in cancers</article-title>. <source>J Vis Exp</source>
<year>2011</year>;<volume>21</volume>:<fpage>3357</fpage>.</mixed-citation></ref><ref id="CIT0054"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hura</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Sawant</surname>
<given-names>AV</given-names></string-name>, <string-name><surname>Kumari</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Combretastatin-inspired heterocycles as antitubulin anticancer agents</article-title>. <source>ACS Omega</source>
<year>2018</year>;<volume>3</volume>:<fpage>9754</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">31459105</pub-id></mixed-citation></ref><ref id="CIT0055"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ayati</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Esmaeili</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Moghimi</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and biological evaluation of 4-amino-5-cinnamoylthiazoles as chalcone-like anticancer agents</article-title>. <source>Eur J Med Chem</source>
<year>2018</year>;<volume>145</volume>:<fpage>404</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">29335206</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mahapatra</surname>
<given-names>DK</given-names></string-name>, <string-name><surname>Bharti</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Asati</surname>
<given-names>V.</given-names></string-name></person-group>
<article-title>Anti-cancer chalcones: structural and molecular target perspectives</article-title>. <source>Eur J Med Chem</source>
<year>2015</year>;<volume>98</volume>:<fpage>69</fpage>&#x02013;<lpage>114</lpage>.<pub-id pub-id-type="pmid">26005917</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Yan</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Cao</surname>
<given-names>D</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis and biological evaluation of 4-anilinoquinoline derivatives as novel potent tubulin depolymerization agents</article-title>. <source>Eur J Med Chem</source>
<year>2017</year>;<volume>138</volume>:<fpage>1114</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">28763646</pub-id></mixed-citation></ref><ref id="CIT0058"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Agha</surname>
<given-names>KA</given-names></string-name>, <string-name><surname>Abo-Dya</surname>
<given-names>NE</given-names></string-name>, <string-name><surname>Ibrahim</surname>
<given-names>TS</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>N-acylbenzotriazole: Convenient approach for protecting group-free monoacylation of symmetric diamines</article-title>. <source>Monatsh Chem</source>
<year>2020</year>;<volume>151</volume>:<fpage>589</fpage>&#x02013;<lpage>98</lpage>.</mixed-citation></ref><ref id="CIT0059"><label>59</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Florian</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Mitchison</surname>
<given-names>TJ.</given-names></string-name></person-group>
<chapter-title>Anti-microtubule drugs</chapter-title>. In: <person-group person-group-type="editor"><string-name><surname>Chang</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Ohi</surname>
<given-names>R</given-names></string-name></person-group>, ed. <source>The mitotic spindle</source>. <publisher-loc>New York (NY)</publisher-loc>: <publisher-name>Humana</publisher-name>; <year>2016</year>:<fpage>403</fpage>&#x02013;<lpage>421</lpage>.</mixed-citation></ref><ref id="CIT0060"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ansari</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Shokrzadeh</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Karima</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>New thiazole-2 (3h)-thiones containing 4-(3, 4, 5-trimethoxyphenyl) moiety as anticancer agents</article-title>. <source>Eur J Med Chem</source>
<year>2020</year>;<volume>185</volume>:<fpage>111784</fpage>.<pub-id pub-id-type="pmid">31669850</pub-id></mixed-citation></ref><ref id="CIT0061"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Greene</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Meegan</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Zisterer</surname>
<given-names>DM.</given-names></string-name></person-group>
<article-title>Combretastatins: More than just vascular targeting agents?</article-title>
<source>J Pharmacol Exp Ther</source>
<year>2015</year>;<volume>355</volume>:<fpage>212</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">26354991</pub-id></mixed-citation></ref><ref id="CIT0062"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Agut</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Falomir</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Murga</surname>
<given-names>J</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis of combretastatin a-4 and 3&#x02032;-aminocombretastatin a-4 derivatives with aminoacid containing pendants and study of their interaction with tubulin and as downregulators of the vegf, htert and c-myc gene expression</article-title>. <source>Molecules</source>
<year>2020</year>;<volume>25</volume>:<fpage>660</fpage>.</mixed-citation></ref><ref id="CIT0063"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>P&#x000e9;rez-P&#x000e9;rez</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Priego</surname>
<given-names>EM</given-names></string-name>, <string-name><surname>Bueno</surname>
<given-names>O</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Blocking blood flow to solid tumors by destabilizing tubulin: An approach to targeting tumor growth</article-title>. <source>J Med Chem</source>
<year>2016</year>;<volume>59</volume>:<fpage>8685</fpage>&#x02013;<lpage>711</lpage>.<pub-id pub-id-type="pmid">27348355</pub-id></mixed-citation></ref><ref id="CIT0064"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shobeiri</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Rashedi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mosaffa</surname>
<given-names>F</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and biological evaluation of quinoline analogues of flavones as potential anticancer agents and tubulin polymerization inhibitors</article-title>. <source>Eur J Med Chem</source>
<year>2016</year>;<volume>114</volume>:<fpage>14</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">26974371</pub-id></mixed-citation></ref><ref id="CIT0065"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mendez</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Policarpi</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Cenciarelli</surname>
<given-names>C</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Role of bim in apoptosis induced in h460 lung tumor cells by the spindle poison combretastatin-a4</article-title>. <source>Apoptosis</source>
<year>2011</year>;<volume>16</volume>:<fpage>940</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21671007</pub-id></mixed-citation></ref><ref id="CIT0066"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tarade</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Ma</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Pignanelli</surname>
<given-names>C</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structurally simplified biphenyl combretastatin a4 derivatives retain in&#x000a0;vitro anti-cancer activity dependent on mitotic arrest</article-title>. <source>PLoS One</source>
<year>2017</year>;<volume>12</volume>:<fpage>e0171806</fpage>.<pub-id pub-id-type="pmid">28253265</pub-id></mixed-citation></ref><ref id="CIT0067"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Naaz</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Ahmad</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Lone</surname>
<given-names>BA</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design and synthesis of newer 1,3,4-oxadiazole and 1,2,4-triazole based topsentin analogues as anti-proliferative agent targeting tubulin</article-title>. <source>Bioorg Chem</source>
<year>2020</year>;<volume>95</volume>:<fpage>103519</fpage>.<pub-id pub-id-type="pmid">31884140</pub-id></mixed-citation></ref><ref id="CIT0068"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hua</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Gou</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>Dual-functional conjugates improving cancer immunochemotherapy by inhibiting tubulin polymerization and indoleamine-2,3-dioxygenase</article-title>. <source>Eur J Med Chem</source>
<year>2020</year>;<volume>189</volume>:<fpage>112041</fpage>.<pub-id pub-id-type="pmid">31954880</pub-id></mixed-citation></ref><ref id="CIT0069"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bortolozzi</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Carta</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Dal Pr&#x000e0;</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Evaluating the effects of fluorine on biological properties and metabolic stability of some antitubulin 3-substituted 7-phenyl-pyrroloquinolinones</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>;<volume>178</volume>:<fpage>297</fpage>&#x02013;<lpage>314</lpage>.<pub-id pub-id-type="pmid">31195171</pub-id></mixed-citation></ref><ref id="CIT0070"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xiong</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Mu</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>X.</given-names></string-name></person-group>
<article-title>Mitochondria-mediated apoptosis in mammals</article-title>. <source>Protein &#x00026; Cell</source>
<year>2014</year>;<volume>5</volume>:<fpage>737</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">25073422</pub-id></mixed-citation></ref><ref id="CIT0071"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname>
<given-names>YR</given-names></string-name>, <string-name><surname>Jia</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>YJ</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>XZ.</given-names></string-name></person-group>
<article-title>Novel dibenzoxanthenes compounds inhibit human gastric cancer sgc-7901 cell growth by apoptosis</article-title>. <source>J Mol Struct</source>
<year>2020</year>;<volume>1220</volume>:<fpage>128588</fpage>.</mixed-citation></ref><ref id="CIT0072"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Romagnoli</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Baraldi</surname>
<given-names>PG</given-names></string-name>, <string-name><surname>Prencipe</surname>
<given-names>F</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design and synthesis of potent in&#x000a0;vitro and in&#x000a0;vivo anticancer agents based on 1-(3',4',5'-Trimethoxyphenyl)-2-Aryl-1H-Imidazole</article-title>. <source>Sci Rep</source>
<year>2016</year>;<volume>6</volume>:<fpage>26602</fpage>.<pub-id pub-id-type="pmid">27216165</pub-id></mixed-citation></ref><ref id="CIT0073"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Romagnoli</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Baraldi</surname>
<given-names>PG</given-names></string-name>, <string-name><surname>Prencipe</surname>
<given-names>F</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and biological evaluation of 2-methyl-4,5-disubstituted oxazoles as a novel class of highly potent antitubulin agents</article-title>. <source>Sci Rep</source>
<year>2017</year>;<volume>7</volume>:<fpage>46356</fpage>.<pub-id pub-id-type="pmid">28406191</pub-id></mixed-citation></ref></ref-list></back></article>